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This study aims at identifying the challenges being faced by NAFDAC in the monitoring of 
adverse drug reactions (ADRS) and to proffer solutions for the purpose of enhancing 
pharmacovigilance activities in Nigeria. To achieve this, the study sought to determine if 
NAFDAC has the capability to monitor and address reported ADR cases, to identify the factors 
that hinder the effective monitoring of ADRs and to suggest recommendations that can 
improve the level of ADR monitoring in Nigeria.  
In conducting this study, the quantitative approach was used. A sample size of 152 was 
generated and data was collected through the aid of close-ended electronic survey 
questionnaires. Out of the 152 questionnaires administered to respondents, only 139 was 
answered and submitted. This shows a response rate of 91%. Descriptive statistics with the 
aid of the Statistical Package for Social Sciences (SPSS) version 20.0 was used to analyse 
obtained data and results were presented in frequencies and percentages in tables, pie charts 
and bar charts. In testing the study’s hypotheses, simple linear regression and Karl Pearson’s 
correlation were used. 
Findings from the study revealed that poor and inconsistent training of staff on recent 
developments in ADR monitoring, neglect of latest technological solutions in the monitoring 
of ADR, reluctance of most healthcare professionals to report ADR issues and the refusal of 
drug users to report experienced ADR issues remain the main factors that hinder NAFDAC 
from effectively carrying out ADR monitoring in the nation. The study recommends that 
regular trainings where staff’s knowledge are updated with current trends regarding ADR 
monitoring should be conducted. Also, NAFDAC should adopt the use of latest technological 
solutions in the monitoring practice of ADRs. Emphasis should be placed on the use of 
digitised reporting system to make the tracking of ADR cases easier and faster and a well-
designed educational program should be implemented to enlighten medical practitioners and 
users of pharmaceutical products on the need for the reporting of known ADR issues. 
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CHAPTER ONE: INTRODUCTION 
1.1 OVERVIEW 
For centuries, the global society has experienced various forms of diseases which have sent 
many to their early graves. As each year passes, the rate of diseases has been observed to 
increase exponentially with a higher fraction being in third-world countries. This phenomenon 
reveals the burden of responsibility that lies on medical practitioners to seek out ways 
through which public health can be protected both in developed and developing nations. With 
medical practitioners having this understanding, several drugs have been manufactured and 
used in order to cushion the effect these diseases have on the public health of a nation. 
According to Meyer (2003), a drug is defined as a single active chemical body present in a 
medicine that is used for the diagnosis, prevention and treatment of diseases. However, the 
production and use of these drugs have led to some reactions that are seen to be detrimental 
to the good health of individuals. These reactions are referred to as adverse drug reactions 
and have been observed to differ from people to people as Meyer (2000) affirmed that one 
of the major problems in clinical practice and drug development is the difference in people’s 
reactions to drugs administration. Adverse drug reaction refers to any noxious accidental and 
undesired effects of a drug that occur at doses used for the prevention, diagnosis or treatment 
of diseases (Shibbiru and Tadesse, 2016).  
In medical history, almost six decades ago, the adverse reaction of a drug named 
“Thalidomide” was known to be responsible for the largest man-made medical catastrophe 
ever known by man (Vargesson, 2015). This drug which was initially produced for the 
treatment of morning sickness in pregnant women cost the lives of at least 2,000 children and 
deformation of over 10, 000 children. Prior to this time, regulation of drug safety was not 
given serious attention; not until 1961 where the drug was banned from the market after 
much damage had been done.  This prompted the need for monitoring the safety of drugs 
after-market authorisation must have been given (Santosh and Tragulpiankit, 2011). And this 
monitoring responsibility demands that medical institutions and agencies develop vigilant 
measures to ensure the rate of reactions is drastically reduced.   
Adverse drug reaction monitoring is the continuous follow-up of unwanted effects observed 
to come from the use of medical products. Sahu, Yadav, and Chandrakar (2014) defined it as 
the practice of constantly monitoring the undesirable effects caused from the use of drugs. 
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Shashi et al. (2016) defined monitoring as a process of evaluating a volatile system in order to 
guide changes to the system for maintenance or improvement. According to the American 
Society of Hospital Pharmacists (ASHP) (n.d.), the monitoring and reporting of ADR entails the 
observation of ADRs, documentation of ADR cases, reporting of ADRs, establishing a 
framework that allows for monitoring the safety of drug use in highly vulnerable patient 
population, and finally involves the enlightenment of medical practitioners concerning 
potential ADRs. All these features must be in a good ADR monitoring program.  
Several benefits seem to exist from ADR monitoring programs to medical practitioners, 
patients and the public at large. The implementation of ADR monitoring programs propels the 
evaluation of the degree to which a drug is safe and allowed for use on people. This reduces 
the rate to which drugs have adverse effects on people, thereby improving the health of the 
general public. Also, medical practitioners who appear ignorant of certain adverse drug 
effects are enlightened and shown ways through which these effects can be tackled on 
patients. When adverse drug reactions are reduced, there is a reduced level of hospitalisation, 
implying that more people are in good health to go about their routine activities. This 
therefore impacts positively on the economy.  
As earlier mentioned, responsibility lies on all medical practitioners, clinicians, dentists, 
pharmacists, nurses, patients to ensure ADR cases are adequately monitored. ADR monitoring 
should cover all pharma products, biological, herbal drugs, cosmetics and devices. This is to 
ensure mitigation of the rate of ADR cases from all corners and ensure the health of the public 
is highly protected.  
The significant role these healthcare professionals play in the treatment of diseases for the 
good health of the general public cannot be overemphasised. Through their large amount of 
steady investment in research and development (R&D), pharmaceutical companies have 
always made efforts to ensure that drugs produced meet the standard requirement in terms 
of quality, efficacy and safety. Despite this, there is still the cogent need for regulatory 
agencies as they ensure the strict adherence to laid-out procedures through all phases of 
clinical trials and post-market authorisation for the purpose of having the best possible 
outcome for new medicines. Before clinical trials, preclinical trials are usually done on animals 
to ascertain whether it is safe for trials on humans. Five phases of clinical trials seem to exist. 
These phases include, phase 0, phase 1, phase 2, phase 3 and phase 4. Phase 0 is simply a 
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guide to phase 1. It is conducted on a small number of people normally less than 15 to 
establish a certain degree of safety. Here, medical researchers administer a very minute dose 
on these small number of people to ascertain a certain degree of safety before administering 
it in greater quantity in other phases. In Phase 1, a longer duration of time is spent by medical 
researchers in observing the effects of the newly developed drug on a larger number of 
people usually between 20 and 80. The major aim of this phase is to identify the highest 
dosage that can be consumed by a human being without any adverse effects. Phase 0 and 
Phase 1 usually involve participants who have no underlying health conditions. Phase 2 
involves increasing the number of people to increase the confidence in safety level of the 
drug. Here, the new drug is tried on hundreds of people who are known to have the illness 
for which the drug was developed to treat. The same dosage given to those in the preceding 
stage which was discovered to be safe is administered to participants in this phase. Phase 3 
is a more confirmatory phase to conclude on the safety of the drug while Phase 4 is the stage 
where the drugs are monitored to ensure its safety after it has been approved into the 
market. It is at this stage pharmacovigilance comes into play and it usually characterises a 
longer period of time than previous phases. This phase is very important to test the safety of 
the drugs because they are being used by a larger population and therefore there is the need 
for pharmacovigilance activities like adverse drug reaction monitoring to further protect the 
health of the public. 
Pharmacovigilance is a word derived from French roots and it is defined as “a cyclic process 
of signal detection, signal strengthening and follow-up” (Santosh and Tragulpiankit, 2011). 
This means it is a recurring process that involves the careful observation and analysis of 
related drug-adverse events or cases via different medical perspectives with the focus of 
constantly improving the reliability of the process and comparing results obtained with 
another. The World Health Organisation (WHO) (2004) defined pharmacovigilance as the 
“science and activities relating to the detection, assessment, understanding and prevention 
of adverse effects or any other possible drug-related problems”. The significance of 
pharmacovigilance to the safety of drugs cannot be overemphasised as it is the sole means 
through which the safety of drugs can be ensured and assured through the drug’s lifecycle. 
Adopting clinical trials are good but clinical trials are not enough to ensure the safety of a drug 
when it has been pushed into the market. Clinical trials as earlier revealed are done prior to 
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the market authorisation of drugs. Pharmacovigilance on the other hand is the only means 
through which the safety of drugs on individuals are monitored or observed after they have 
been pushed into the market. It can be said that pharmacovigilance is post-market 
observation of drugs safety. 
In the literature and even practically, the term adverse drug reaction (ADR) and adverse drug 
event (ADE) have been mistaken to be synonymous concepts. But there exists a difference 
between them. The WHO (2005) explained adverse drug event (ADE) to be any unpleasant 
medical event that occurs when drugs are administered to a patient but are not necessarily 
the cause of that event. This means ADE are unexpected negative circumstances that occur 
during the treatment of a patient of which the treatment is not the cause. Adverse drug 
reaction (ADR) on the other hand, as defined by WHO (1972) is “a response to a drug which 
is noxious and unintended, and which occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease or for the modifications of physiological 
function.” Scholars and practitioners should be able to tell the difference between these two 
concepts. 
Adverse drug reactions could be mild or harsh when drugs are administered to patients. They 
are to be termed serious when patients as a result of a dose administered become disabled 
with even the possibility of death and also when certain behaviours shown by the patients 
are not in line with what is stated in the Patient Information Leaflets (PILs). 
Meyboom et al. (1997) having reviewed works done by other researchers, said that ADR may 
somehow be unnaturally categorised into three different types: A, B and C. This was also 
supported by Schatz and Weber (2015) who revealed that ADRs were initially categorised into 
two subtypes. Type A ADRs are reactions that come as a result of the administration of 
overdose to a patient. They are usually known and predictable due to the pharmacological 
effects inherent in the drug. Simply, type A ADRs are reactions that can be determined from 
the known pharmacology of a drug. Type A ADRs are one of the commonest and most 
frequent ADR and can be easily avoided by using the right amount of dosage for a patient. 
They can also be addressed by reducing the dose given to the patient. An example of Type A 
ADRs is constipation induced by morphine and it can be easily identified before its entrance 
into the market and can be experimentally studied and reproduced. However, certain issues 
can arise from this which include: 
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• A minority of the patients are showing this effect 
• When no correlation exists between the effect and the drug dosage.  
• When the issue is not important, concurrent or to reproduce in experiment is very 
difficult 
• When it is not a clear process 
A typical example for this is the cough inherent in the use of Captopril and other angiotensin-
converting enzyme (ACE) inhibitors. This was not observed during the clinical trials but was 
noticed due to monitoring after allowed into the market. Other examples include bleeding, 
postural hypotension etc.  
Type B ADRs on the other hand are not as common as Type A and are usually unpredictable 
for a number of reasons which may not have any correlation with the use of the drugs. They 
are independent of dosage and are observed in a small population of patients implying that 
the different traits of patients are the determining factors for the reactions observed 
(Pirmohamed and Park, 2003). Simply, Type B reactions are reactions that cannot be 
determined from the pharmacology of a drug. They are more dependent on the individual 
trait of the patients than of the dose administered. Type B ADRs are also called “patients’ 
reactions”. They are often serious and are difficult to detect. A major reason for all the 
features mentioned in Type B is the correlation with time and little backdrop frequency that 
usually give good reasons to make the drug a suspect. Type B ADRs are mostly allergies; for 
example, allergy to drug like penicillin leads to anaphylaxis while allergy to anticonvulsant 
leads to hypersensitivity, etc. Schatz and Weber (2015) revealed that type A reactions were 
later referred to as augmented while type B reactions were referred to as bizarre: Type A 
reactions are simply as a result of overdosage (i.e. dose related) while type B are strange 
reactions, non-dose related which were not earlier anticipated due to the variations in the 
traits of patients.  
Type C ADRs are those reactions that are dose related and time related. The production of 
drugs for the past five decades has greatly ameliorated the quality and expectancy of life for 
people with chronic diseases. However, there have been some vivid changes in some diseases 
like diabetes mellitus and myasthenia gravis and the problems of late sickness are now 
determined by the well-being and diagnosis of patients. The type C reactions usually come as 
a result of the accumulation of dose or with a use of such drugs for a long period of time. The 
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frequency in the occurrence of natural sickness are determined by the prolonged use of such 
drugs over a period of time. This is also detrimental to the health of the public. An example is 
adrenal suppression with corticosteroids. Another example is the effect oral contraceptives 
have on the commonness of breast tumours or thromboembolic complications with several 
oral contraceptives.  
Further to the above subtypes of ADRs, other types emerged. The first one is the type D ADR. 
The type D ADR is a type of delayed reaction. It occurs after a long period of treatment and 
can be as a result of accumulation. An example of this reaction is secondary tumours from 
chemotherapy, nephropathy from analgesics, etc. Type E ADR which is another type of ADR 
occurs when treatment using a particular drug on a patient is abruptly put to a stop. For 
instance, the abrupt withdrawal of phenytoin leads to seizures. Summarily, any reaction that 
occurs immediately after the stoppage of the administration of a drug is called the type E 
ADR.   
Types of ADRs Examples 
Type A Constipation induced by morphine 
Type B (i) Allergy to drug like penicillin 
leads to anaphylaxis 
(ii) Allergy to anticonvulsant leads to 
hypersensitivity 
Type C (i) Adrenal suppression with 
corticosteroids 
(ii) Thromboembolic complications 
with several oral contraceptives.  
Type D (i) Secondary tumours from 
chemotherapy 
(ii) Nephropathy from analgesics 
Type E The abrupt withdrawal of phenytoin leads to 
seizures. 
i Table 1: Types of ADRs and Their Examples 
Consequent upon the foregoing, pharmacovigilance which encompasses all the processes 
involved in the detection, examination, comprehension and prevention of ADRs was 
introduced for the purpose of enhancing the safety and balanced use of drugs in order to 




THE REGULATORY AFFAIRS 
For every system or structure, there is always an entity charged with the responsibility of 
monitoring and coordinating its affairs for the successful attainment of goals. In medical 
sciences, several regulatory frameworks are set up to ensure the adequate monitoring of its 
activities. As regards the safety of drugs, it is the major responsibility of the regulatory affairs 
to ensure safe, effective and high-quality drugs are made available for public use. It is the duty 
of the regulatory affairs to enact and enforce strict adherence to pharmaceutical regulations 
related to research and development, drugs registration, manufacturing, principle, delivering, 
protection of intellectual property and sales. The principal aim of the regulatory affairs is to 
protect patients from unintentional harm from previously unidentified hazard of the drug. 
Subsequent to the medical catastrophe that occurred in the early twentieth (20th) century, 
the “thalidomide case”, the safety concern on all pharmaceutical products greatly intensified. 
This prompted thorough vigilance in the inspection process of all pharmaceutical products 
before and after authorisation into markets. This activity became inevitable in order to 
prevent a reoccurrence of the “thalidomide case”. The World Health Organisation (WHO) 
through its comprehensive drug control programme in 1968 encouraged the implementation 
of pharmacovigilance in every member nation. All member nations kept up with a single 
contact-point to collect, review and exchange data from the several incident reports around 
the globe.  
In 2005, the WHO stated in their first set of regulations published, that a hospital or third-
party health facility containing more than fifty (50) admission beds needs the services of a 
pharmacovigilant contact person in order to promote the activities of pharmacovigilance like 
ADR monitoring and reporting, provision of adequate education and training of medical 
personnel for the better medical care of patients. 
In Nigeria for instance, the regulatory affairs responsible for the monitoring and coordination 
of all pharmacovigilance activities is the National Pharmacovigilance Centre (NPC) under the 
supervision of the National Agency for Food Drugs and Administration Control (NAFDAC). 
NAFDAC which joined the WHO International Drug Monitoring Programme in 2004 has since 




ADR MONITORING AND PHARMACOVIGILANCE 
The principal role of every regulatory body, in the case of Nigeria, NAFDAC is to ensure the 
consistent, effective monitoring of all marketed drugs for the health of the public. Agencies 
like this are burdened with the responsibility to ensure that drugs authorised for public 
consumption are of no threats to the health of the general public. Owing to the high incidence 
level of adverse drug reactions in the globe especially Nigeria, the significance of 
pharmacovigilance activities cannot be excused. Pharmacovigilance which has been defined 
by WHO (2002) as “the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other possible drug-related 
problem”. Yadav (2008) revealed that the term pharmacovigilance is founded upon three (3) 
pillars which are as follows: 
(i) Obtaining of new information from trusted scientific resources like marketing 
authorisation holders, healthcare professionals, consumers, international/public 
bodies, journals, published and updated literature, etc. 
(ii) Classification and examination of the above information. 
(iii) Circulation of its contents as well as any action taken on specific drug to all health 
sectors.  
   




Yadav (2008) further stated that every ADR report should have the following features which 
are: (a) patient (b) a drug (c) an adverse reaction (d) composer/reporter of the report. Without 
these characteristics, such report is just a mere report and nothing more.  
Several studies have revealed some factors that hinder ADR monitoring by medical 
practitioners in the globe. With respect to Nigeria, Ezeuko, Ebenebe, Nnebue and Ugoji 
(2015), identified some of these factors to include ignorance of pharmacovigilance program, 
absence of a pharmacovigilance feedback system and methodology for detecting warnings, 
etc. It is of utmost important for these issues to be addressed since health practitioners (both 
medical doctors and pharmacists) are the ones responsible for the treatment and care of 
patients. Attention has to be paid to medical practitioners understanding the significant role 
pharmacovigilance plays in the health of the public. Moreover, the agency responsible for the 
supervision of pharmacovigilance activities in Nigeria, NAFDAC has been bequeathed with 
some challenges that affect the proper monitoring of ADR cases in Nigeria.   
1.2 Research Purpose 
The study is underlined with the purpose of identifying and exploring the challenges faced by 
the National Agency for Food Drug Administration and Control (NAFDAC) in monitoring ADR 
for ameliorating practices in the area of drug safety, reducing the cost of ADR in Nigeria 
general patient population, improving the rate of reporting, and removing any encumbrances 
that may hinder the effective impact of NAFDAC. Most of the ADR cases in Nigeria are 
consequent upon some issues like the drug’s wrong information, advanced age-related 
physiological, biochemical, pharmacokinetics, pharmacodynamics, and abuse. And 
sometimes, the severity of the ADRs seems to outweigh the benefits which the drug proposes. 
It is in this event NAFDAC is meant to intervene, but some factors exist that hinder them from 
effectively carrying out their duty.  
To proffer solution to this problem faced by NAFDAC, the researcher further evaluated the 
level of information obtained by NAFDAC staff on ADR monitoring and pharmacovigilance 
activities at large. It is obvious that the rate of ADR monitoring in Nigeria is low, this study 
seeks to provide ways through which ADR monitoring can be improved for the safety and 
good health of both patients and the general public in Nigeria.  
18 
 
1.3 Significance of the Study 
The National Agency for Food Drug and Administration Control (NAFDAC) through the arm of 
the National Pharmacovigilance Centre (NPC) is known to be responsible for handling all 
pharmacovigilance activities in Nigeria. The monitoring of ADRs have become an issue of 
paramount concern in the medical field due to the increased mortality rate and low life 
expectancy in the country as revealed by Shelton (2014). There is a need to further the 
examination of ADRs in hospitals and various medical facilities in order to identify the benefit-
risk ratio of drugs for the safety of public health.  Moreover, to further safeguard the health 
of the public, a need for placing emphasis on drug control is crucial for the restructuring and 
enforcing of an optimal ADR protocol system which spans from the recruitment process 
through to the laboratory parameters. In spite the importance of ADR monitoring to medical 
institutions and patients, the rate at which this activity is carried out is appalling. This study 
seeks to reveal the factors that hinder the effective monitoring of ADRs by the regulatory 
body in Nigeria.  
1.4 Research Objectives 
1. To determine if NAFDAC possesses the capability to monitor and address reported 
ADR cases. 
2. To identify the factors that hinder NAFDAC from effectively monitoring ADR in Nigeria. 
3. To proffer solutions that will help boost ADR monitoring by NAFDAC. 
1.5 Research Questions 
1. Does NAFDAC have the capability to monitor and address the reported ADR cases? 
2. What are the factors that hinder NAFDAC from effectively monitoring ADR in Nigeria? 
3. What are some possible solutions that will help boost ADR monitoring by NAFDAC? 
1.6 Research Hypotheses 
Hypothesis One: 
H0: NAFDAC ADR monitoring would have no impact on the safety of public health. 
H1: NAFDAC ADR monitoring would have an impact on the safety of public health. 
 
Hypothesis Two: 
H0: No relationship exists between ADR monitoring and reduction in ADR cases. 
H1: A relationship exists between ADR monitoring and reduction in ADR cases. 
1.7 Structure of the Study 
This study is premised upon the epistemological approach of positivism. Due to this, a 
quantitative approach was adopted in obtaining data. The primary research of this study was 
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aided through the use of electronic survey questionnaires. The questionnaires were 
structured to obtain information from staff of NAFDAC Lagos Operational Office located at 
Plot 1, Industrial Estate, Lagos, Oshodi-Apapa Expressway, Isolo, Lagos, Nigeria. The 
questionnaires were divided into two categories, section A and section B. Section A is 
concerned with the socio-demographic information of respondents while section B has to do 
with items that relate with the variables of the topic. 
Moreover, the study comprises five chapters. Chapter one is the introductory chapter which 
encompasses an overview of the study, research questions, research objectives, research 
hypotheses and significance of the study. Chapter two on the other hand concerns reviewed 
literatures related to the study’s topic and empirical findings while chapter three deals with 
the methodology adopted in providing answers to the research questions. Chapter four 
majorly has to do with the presentation and interpretation of data and how they connect with 
existing literature. Chapter five which is the final chapter is the concluding part of the study. 
It clearly reveals the answers to the research questions and recommends solutions for 
practice and future research.  
1.8 Conclusion 
With Nigeria being a large market for various products due to its population strength, it is 
expedient that several measures be put in place to monitor the standard of these products 
both shipped into its boundaries and locally produced. Of course, medical products are no 
exception instead, a greater degree of attention are to be paid to them given their direct 
impact on public health. This awareness prompts the need for the regulatory agency, NAFDAC 
through the NPC to intensify efforts on promoting pharmacovigilance activities especially ADR 
monitoring in Nigeria. However, in an attempt to promote pharmacovigilance activities in the 
country, NAFDAC is faced with some challenges that inhibits its effective implementation. This 
calls for some investigations to seek out the root causes of these challenges and proffer 
solutions to them. The monitoring of ADR cases in the Nigerian medical market cannot be 
comprised or taken for granted due to the significant role it plays in the protection of the 
health and safety of the general public. Hence, it is pertinent to ensure the establishment of 




CHAPTER TWO: LITERATURE REVIEW 
2.1 INTRODUCTION 
Nigeria as a whole has for a long time been characterised by several challenges in the medical 
sphere. This has given rise to increased mortality and morbidity rates in the nation. In addition 
to the challenges faced, there exists a low level of monitoring of adverse drug reactions. Drugs 
being authorised into the market are scarcely monitored to ascertain if there exist other side 
effects not observed in the clinical trials. The regulatory agency responsible for the monitoring 
of drugs in the post-market authorisation period have not been effective in the dispensing of 
their duties and this has contributed to the increased rate of mortality and morbidity 
experienced in the country.  This chapter deals with the extant literature on issues pertaining 
to ADR monitoring in Nigeria revealing challenges being faced by the regulatory agency in the 
discharge of their duties.   
2.2 BRIEF OVERVIEW OF NIGERIA 
Nigeria is known to be the most populous nation in Africa located in the West African sub-
region and is popularly referred to as the “Giant” of the continent, bordering Benin in the 
west, Chad in the northeast, Niger in the north and Cameroon in the east. Nigeria is a country 
that comprises thirty-six (36) states and its capital city, Abuja. The World Population Review 
(2020) revealed the Nigerian population to be over 205 million people, making the country 
the seventh largest in the world. Lagos state, the former capital of the nation inhabits a higher 
percentage of the population than other states with an estimate of 14,368,332 (World 
Population Review, 2020). As a developing nation, it has been characterised by lots of health 
and medical related issues, though the morbidity and the mortality has not been quantified 
yet (Olowofela, Fourrier-Réglat and Isah, 2016) and has been known to have the lowest life 
expectancy rate in the West Africa sub-region (NATIONAL BUREAU OF STATISTICS, 2020). 
The World Health Organisation (W.H.O.) has estimated the life expectancy of Nigerians to be 
54.5 years of age ranking Nigeria as the fifth behind Central African Republic, Lesotho, Chad, 
and Sierra Leone. The low life expectancy in Nigeria is contingent upon several factors of 
which the low standard of medical facilities is a major one. The diagram below shows a 





Figure 2: A Graphical Representation of Infant Mortality Rate from 2008 to 2018 
(Statista, 2020) 
The above graphical representation shows the mortality rate of infants between the year 
period of 2008 and 2018. From Fig. 2 it is seen that the infant mortality rate is on a 
downward trend. Despite the decreasing rate of infant mortality rate in Nigeria, UNICEF 
has revealed that Nigeria is still one of the countries with the highest infant mortality rate 
in the world (TRTWorld, 2019). Statistics shows that every five children have the tendency 
to die before reaching the age of five. A major factor responsible for this is the poor 
medical structure prevalent in the country. The high rate of health issues in the country 
seems to be beyond the capacity of the medical system available in the nation. 
Nonetheless, the population of the country is seen to be on the rise with a percentage 
increase of 3.2 percent annually (VOA, 2019) which is high when compared to other 
countries.  As predicted by the United Nations (UN), the overall population of Nigeria is 
estimated to be about 401.31 million people by 2050 and if the following figure remains 




Figure 3: Growth Rate of Nigeria’s Population 
(http://worldpopulationreview.com/countries/nigeria-population - Google Search, 2020) 
2.3 THE CURRENT STATE OF ADVERSE DRUG REACTION ACTIVITIES IN NIGERIA  
Nigeria has been known to inhabit an epileptic medical system featured by insufficient 
and inadequate equipment, poor compensation package for medical personnel, poor 
infrastructural facilities and so on. This of course has contributed to the rate of mortality 
and morbidity in the country. The low rate of monitoring ADR cases in the country is also 
an offshoot of the epileptic medical system. According to Premium Times (2016), the 
National Agency for Food and Drugs Administration and Control (NAFDAC) in a bid to 
ensure effective ADR monitoring, through its former acting Director-General, Yetunde Oni 
advocated for the consistent reporting of ADR cases from all medical institutions in order 
for the agency to take necessary actions. She further revealed that:  
Due to the inherent nature of medicines, no medicine, no matter how skilfully produced 
to meet specified quality standards, properly distributed and stored, rationally 
prescribed and used is 100 percent safe…However, by continuously monitoring all 
medicines, it is possible to detect those causing unwanted ADRs, understand why they 
cause ADRs and prevent them from further causing harm to users. This can only be 
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done effectively if health care providers detect and report all suspected ADRs and other 
medicine related problems. 
Recall that ADRs are effectively monitored when all medical practitioners pay attention to 
detection and reporting of suspected cases in every medical institution. This is because 
medical practitioners especially doctors are usually the first point-of-call for any disorder 
experienced by patients in their health. As a result, responsibility is bequeathed on them 
for the detection and reporting of every suspected ADR case.  
In 2004, the National Pharmacovigilance Centre (NPC) was officially launched for the 
purpose of ameliorating the safety of patients in the use of drugs. As revealed by Oni 
(Premium Times, 2016), every nation that has adopted the pharmacovigilance program is 
required to have at least two hundred individual safety report case per a million residents 
in a year. In 2013, 2014, 2015, the number of ADR cases reported was 2162, 988, and 1385 
respectively. Moreover in 2016 where the population of Nigeria was estimated to be over 
140 million people, the number of reported cases was only 2361. This means Nigeria was 
supposed to have at least 28,000 cases per year, but this was only an illusion because the 
data revealed from the agency showed only 2361 cases were reported for that year. These 
figures indicate that a lot of ADR cases are not reported; and if finally reported, many of 
those cases are not documented. The non-reporting of these cases implies no action taken 
which further means that the health and safety of Nigerians are at a huge risk (Adebowale, 
2016).  
Opadeyi, Fourrier-Reglat and Isah (2018) in their study, exposed more on the current state 
of pharmacovigilance in Nigeria. According to them, the level of pharmacovigilance 
activities in Nigeria is still in the teething stage. Low level of ADR monitoring seems to 
characterise the Nigeria medical system due to the poor documentation and huge neglect 
for the issue of pharmacovigilance by medical practitioners in the country. Moreover, 
Segun and Fakeye (2013) who ventured into examining the level of awareness had by 
pharmacy students of the subject matter of pharmacovigilance using a Nigerian university 
as a case study, revealed that students appear to be ignorant of the sequence of reporting 
ADR. According to them, this is consequent upon the absence of pharmacovigilance and 
adverse drug reaction courses in the schools of pharmacy curriculum in Nigeria. The lack 
of these courses in pharmacy curriculum means pharmacists churned out into the 
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practical field are not actively involved in the activities of pharmacovigilance which has 
contributed to the low level of monitoring ADR cases in the country. 
Further to the above, in Nigeria, statistics has shown that the elderly, those aged between 
the age of 65 years and above constitute 3.1 percent of the total population and is rapidly 
increasing (cited in Tanyi, Andre, and Mbah, 2018). Recall that Hilliard (2017) reported 
that elderly people are more prone to illnesses than younger individuals by showing that 
52.9 percent of men and 53.5 percent of women above 65 years are seen to suffer from 
severe illnesses or health-related problems. Most of the health problems suffered by 
these elderly individuals could be as a result of complications derived from the 
administration of certain drugs. Beijer and de Blaey (2002) confirmed this by stating that 
a positive correlation exists between adverse drug reactions (ADR) and an increase in age. 
This, they revealed by further explaining that more patients of the age of 65 years and 
above are being hospitalised for ADR-related issues than younger individuals. This implies 
that elderly people suffer more from adverse drug reactions than younger people in 
Nigeria. Some of the drugs used by elderly individuals that causes ADR include 
gastrointestinal drugs, cardiovascular drugs, anti-inflammatory medications and anti-
cancer medications.   
   
Figure 4: Frequency of the medications that cause ADR in patients in Nigeria between December 2013 to August 2014 
(Akhideno, 2019) 
In his study, Akhideno (2019) showed the frequency distribution pattern of patients who 
suffered from ADR and the drug used. In the distribution pattern, insulin was seen to be 
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at the topmost level as shown in Fig. 4, which resulted in more ADR cases in 14 (27.5 
percent) patients. The second was NASIDs which had 10 (19.6 percent) patients followed 
by antihypertensive at 8 (15.7percent) patients, then, antimalaria, herbal medicines and 
antibacterial also being causes of ADR, having 5 (9.8 percent) patients, 4 (7.8 percent) and 
3 (5.9 percent) patients respectively. 
2.4 ADVERSE DRUG REACTION MONITORING  
According to Coleman, Ferner and Evans (2006), monitoring is a process that entails 
examining a system that changes with time for the purpose of guiding those changes in a 
way that will either keep the system in its current state or improve it. Coleman, Ferner 
and Evans (2006) further established that three components characterises a monitoring 
process and they include: proactive and targeted observation, analysis, and action. 
Proactive and targeted observation entails the predetermined phenomena or occurrences 
that are to be observed right before the initiation of the process. This component has to 
be relative to the goal for which the monitoring process is set up. The second component 
which is “analysis” has to do with the examination of the changes required to be made to 
the system for it to maintain its desirable state or move it to a better state. The third 
component which is “action” simply deals with the taking of the steps required to initiate 
the desired changes.  
From the foregoing, adverse drug reaction monitoring is simply a process that entails the 
observation of adverse reactions that are inherent in a drug for the purpose of 
safeguarding the health and safety of a given patient population. It is the continuous 
follow-up of unwanted effects observed to come from the use of medical products. In the 
view of Sahu, Yadav, and Chandrakar (2014), it is the practice of constantly monitoring the 
undesired effects from the use of drugs.  
Adverse drug monitoring is a process that begins right before the time a new drug is 
released into the market. At this stage, it is within the jurisdiction of pharmaceutical 
companies to detect any adverse reaction and therefore provide all the necessary 
information about the new drug. When such drug is released into the market, it is no 
longer the sole responsibility of pharmaceutical companies to provide information about 
adverse reactions of the drug but now requires that all prescribers of the drug do the 
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same. Also, certain organisations are established to carry out this exercise for the safety 
of the drug users.  
A rationale that justifies the post market monitoring of newly developed drugs is that 
during clinical trials, information provided by pharmaceutical companies on the adverse 
reactions inherent in that drug is usually insufficient to ascertain all the possible adverse 
reactions due to the small number of participants used and the short period of time taken 
to examine the drug. This therefore creates the need for post-market surveillance to 
ensure that the drugs remain safe for its continuous consumption by the populace.     
Furthermore, Shashindran and Gitanjali (n. d.) revealed some criteria that should be met 
to determine the existence of adverse drug reactions (ADR) of a particular medication. 
These criteria include the following: 
(i) A temporal connection between the suspected drug and the adverse event. 
(ii) Positive dechallenge: This means improvement in patient’s health or responses 
after withdrawing usage of the drug. 
(iii) Positive rechallenge: This is the recurrence of the adverse event when the 
administration of the drug is resumed. 
(iv) The absence of confounding effect: This means the adverse event has no 
correlation or relationship with any related disease. 
The World Health Organisation (WHO) in 1971 established a global framework for 
monitoring adverse drug reactions using information obtained from member nations. This 
global framework was established as a result of the “thalidomide case” of 1967. Prior to 
this time, issues related to adverse drug reactions were not taken seriously but the advent 
of the “thalidomide case” compelled the WHO to focus on the need for the continuous 
monitoring of drugs even after market authorisation. Due to this, several nations have 
subscribed to the membership of this drug monitoring program. The National Agency for 
Food and Drug Administration Control, NAFDAC, the agency responsible for regulating 
pharmaceutical products in Nigeria joined the WHO International Drug Monitoring 
Program in 2004 to ensure the practice of drug monitoring in the nation aligns with global 




It should be noted that in discussing ADR monitoring, it is expedient that ADR reporting is 
also explained. This is due to the significant role ADR reporting plays in the monitoring of 
adverse reactions of drugs as Gurmesa and Dedefo (2016) stated that ADR reporting aids 
the drug monitoring system to detect the undesired and unintended effects of drugs that 
have already been made available to the public. Adverse drug reaction reporting is simply 
the documentation and presentation of the adverse reactions of drugs to regulatory 
authorities. It is usually done by medical practitioners since they interface with patients 
in the course of administering treatments. It is important for all medical practitioners both 
traditional and modern to report every suspected ADR case to the appropriate authorities 
just as Nadew, Beyene, Beza (2020) stated that the early reporting of ADR cases by 
medical practitioners to regulatory authorities is an insurance for the health and safety of 
the public against the adverse reaction of drugs. The gross negligence by medical 
practitioners in the reporting of ADR cases causes a dysfunction in the monitoring practice 
of ADR cases by regulatory authorities which ultimately puts the entire patient population 
at risk. In affirmation to the preceding, Kavitha (2010), amongst the steps involved in 
adverse drug reaction monitoring, revealed ADR reporting to be inclusive. According to 
her, there are four steps involved in the monitoring of ADRs and they include; (i) detection 
of adverse drug reaction (ii) evaluation of causality between drug and suspected reaction 
(iii) documenting of ADR in patient’s medical records, and (iv) reporting of ADRs to ADR 
regulatory authorities or pharmacovigilance centres.  
2.4.1   ACTORS RESPONSIBLE FOR ADVERSE DRUG REACTION REPORTING IN NIGERIA 
As earlier mentioned, all medical professionals (medical doctors, dentists, midwives, 
nurses, pharmacists, and traditional medicine practitioners) are known to be the first 
point of call when addressing the issue of ADR cases. This is because they are charged with 
the responsibility for the medical care of patients. Given the fact that they constantly 
interface with the illnesses of patients, they are also charged with the responsibility of 
reporting ADR cases when detected. Due to this, the National Agency for Food Drugs 
Administrative Control (NAFDAC), the regulatory agency provides them with the 
necessary support to report any suspected ADR case in the course of duty without 
hesitation. Nonetheless, despite the support provided to these medical personnel, the 
rate of ADR reporting in the nation is seen to be very low. Okezie and Olufunmilayo (2008) 
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concurred to this when they revealed that the rate of reporting by medical doctors was 
low despite their high level of awareness and observation of ADR related issues.  
As aforementioned, the level of ADR reporting in Nigeria is seen to be very poor and this 
is contingent upon various factors like fear of litigation, time constraints, increase in the 
burden of work, etc. Medical doctors most especially have claimed that the reporting of 
ADR cases have the potential to attract litigations and judicial claims against them and 
that the issue of keeping patients’ data confidential is another factor that inhibits the level 
of ADR reporting in the country (Oshikoya and Awobusuyi, 2009). 
More so, the poor training or low level of emphasis on ADR has contributed to the low 
reporting of ADR in Nigeria. This was affirmed by Ezeuko, Ebenebe, Nnebue and Ugoji 
(2015) when it was revealed that out of the 120 doctors surveyed in Lagos State University 
teaching Hospital (LASUTH), Nigeria, only one doctor had received training on the use of 
yellow card in the reporting of ADR. This shows a very high percentage of medical 
practitioners who are unaware of the reporting process of ADR cases. This is abysmally 
bad for a country like Nigeria which inhabits the highest population of people in the 
continent of Africa and whose population is still on an upward trend.  
Comparing the level of ADR cases in Africa to developed countries in the European Union, 
studies have shown both continents to have low level of ADR reporting despite the hike 
in the rate of illnesses in these continents. However, the continent of Africa has been seen 
to have a much lower rate of ADR reporting than its European counterpart. Ampadu et al. 
(2016) affirmed this by stating that though the level of individual case safety reporting in 
Africa has greatly increased, it still comprises less than one percent of the world’s data 
stored in VigiBase. VigiBase is an international database meant for the storing of individual 
case safety reports and is controlled by the Uppsala Monitoring Centre on behalf of the 
World Health Organisation (WHO). Individual case safety reports also simply known as 
safety reports refers to the documenting and reporting of detected adverse reactions of 
a drug(s) to a particular database.  
In 2008, the European Commission revealed that of all hospital admissions, 5 percent are 
as a result of adverse drug reactions (ADR) and that ADR is the fifth commonest cause of 
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deaths in the European Union having a mortality of 197, 000 people per annum. As a 
result, the EU is burdened with a total cost of €79 billion. Furthermore, in a given study 
conducted by the European Commission, a sum total of 4802 patients were admitted and 
recorded. From these patients, about 3.2 percent accounted for those who had ADR 
during their hospitalisation period while 6.2 percent accounted for those who were 
admitted as a result of ADRs. This means a total of 9.4 percent had ADR-related issues out 
of the 4802 patients. It was further observed that the hospitalisation duration was 
prolonged for patients who had ADR issues as against those without ADR issues and also 
patients who receive above four medications were more prone to ADR-related issues. The 
study was of the final conclusion that ADR cases occurred during the period of 
hospitalisation or contributed to the internal drug population of which some or most of 
them could have been prevented. This finding aligns with that of Giardina et al., (2018) 
who were of the opinion that women and patients who consume lots of medications are 
more prone to develop ADR during the period of hospitalisation or as a result of being 
admitted and that of Fasipe, Akhideno, and Owhin (2019) who concluded that ADRs were 
a major determinant for the long hospitalisation period of patients. 
2.5 PHARMACOVIGILANCE IN NIGERIA 
Over the years, Nigeria has constantly been a major market for the local production and 
importation of medicinal products. This is as a result of the increase in the level of diseases 
given the high rate of fertility and the large population it is known to inhabit. Owing to 
this, there is a dire need for vigilance in the monitoring of these locally produced and 
imported drugs for the protection of its entire populace. In an attempt to safeguard the 
health and safety of its entire populace from adverse reactions and possibly poisoning of 
these drugs, Nigeria joined the World Health Organisation (WHO) International Drug 
Monitoring Programme (IDMP) in 2004. This point marked a dramatic change for 
pharmacovigilance in the nation. The subscription of Nigeria to the membership of the 
WHO International Drug Monitoring Programme prompted the establishment of the 
National Pharmacovigilance Centre (NPC) to regulate pharmacovigilance activities in the 




Despite the setting up of this body, the impact of pharmacovigilance activities in the 
nation is still yet to be felt. Nwalwu and Harrison (2014) consented to this by revealing 
that despite medical practitioners having a positive perception of the issue of 
pharmacovigilance, there seems to be little or no practice. This implies that 
pharmacovigilance is more of a theoretical concept than a practical one in Nigeria. 
However, there are a few remarkable feats the National Pharmacovigilance Centre (NPC) 
has achieved in the enforcement of pharmacovigilance in the nation. Several drugs which 
are known to have harsh adverse reactions have been outlawed and banned from the 
Nigerian market. An example is the ban placed on a toxic paracetamol mixed with 
diethylene glycol which cost the lives of a great number of infants and children in 2008. 
Another example is the ban placed in 2005 on dipyrone as a result of the frequent 
injection abscess and strange deaths associated with its use. Regardless of these 
achievements, there is still a lot to do in ensuring the implementation of 
pharmacovigilance activities in the country. This calls for the National Agency for Food 
and Drug Administration and Control (NAFDAC) through the arm of National 
Pharmacovigilance Centre (NPC) to be more vigilant in post-market surveillance in order 
to increase the level of safety in the use of medical products.  
Furthermore, the Nigeria National Drug Policy has revealed that no active drug is 
completely free from adverse reactions. Hence, the government is committed to 
instituting adequately equipped pharmacovigilance centres across the nation for the 
collection, assessment and dissemination of information relating to adverse drug reaction 
cases in the country. The policy further requires that all medical products are monitored 
using efficacy, safety and quality as criteria in order to provide regulatory authorities with 
the right information for necessary actions.  
2.5.1 NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL 
(NAFDAC) 
The National Agency for Food and Drug Administration and Control is a federal agency 
charged with the responsibility of inhibiting the circulation of fake and illegal 
pharmaceutical products in Nigeria. It is an agency that ensures that pharmaceutical 
products released into the market are strictly under the nation’s health and safety 
legislation. The National Agency for Food and Drug Administration and Control was set up 
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by Decree 15 of 1993 under the military regime and was later amended by Decree 19 of 
1999. In 2004, the Decree 19 of 1999 was repealed by the National Agency for Food and 
Drug Administration and Control Act, Cap N1, Laws of the Federation of Nigeria (LFN).  
With its headquarters located at Plot 2032, Olusegun Obasanjo Way, Zone 7, Wuse, Abuja, 
Nigeria, NAFDAC is further responsible for monitoring the production, importation, 
exportation, distribution, advert, sales and consumption of food, pharmaceutical 
products and other inedible products essential for human life in the nation. It aims at 
ensuring the public is aware of basic safety issues and looks to eradicating fake 
pharmaceutical products both locally and internationally produced from the Nigerian 
market.  
2.5.2 NATIONAL PHARMACOVIGILANCE CENTRE 
The National Pharmacovigilance Centre (NPC) is a subdivision of NAFDAC charged with 
the responsibility of overseeing and regulating pharmacovigilance activities in Nigeria. It 
is located at the headquarters of the National Agency for Food Drug Administration and 
Control (NAFDAC) in Abuja, the federal capital of the nation. NPC is a body that receives 
and store spontaneous reports of adverse drug reactions from medical practitioners in 
Nigeria (Olowofela, Fourrier-Réglat and Isah, 2016) and also collaborates with other global 
bodies like the WHO, US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) for the purpose of improving the safety level of drugs in Nigeria.  
Case reports from each state are sent to the zonal centres of NAFDAC via the state 
coordinators which are then forwarded to the National Pharmacovigilance Centre (NPC). 
Subsequent to the reception of these reports by the NPC, necessary actions are taken to 
ensure that drugs available in the market are safe for use by the general patient 
population. Moreover, the NPC implements pharmacovigilance training for medical 
practitioners and other stakeholders in a bid to improve the safe use of drugs in the nation 
(Olowofela, Fourrier-Réglat and Isah, 2016). 
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2.5.3 PHARMACOVIGILANCE STRUCTURE IN NIGERIA 
 
Figure 5: Pharmacovigilance Structure in Nigeria 
(Olowofela, Fourrier-Réglat and Isah, 2016) 
From the diagram above, it could be seen that the National Pharmacovigilance Centre, a 
subdivision of the National Agency for Food and Drug Administration and Control (NAFDAC) 
is at the highest cadre, implying the authority it possesses to oversee and regulate activities 
of pharmacovigilance in Nigeria. On the other hand, the National Drug Safety and Advisory 
Committee (NDSAC) which was established on the 26th of July 2006, was instituted for the 
purpose of evaluating and reviewing of adverse drug reactions in the nation and also provide 
information on any pharmacovigilance case in the country. Formerly being seen as part of the 
Food and Drug Information Centre (FDIC), it later became autonomous to function as a 
committee charged with the responsibility of post-market surveillance and 
pharmacovigilance cases in the country. 
The structure above shows us that the NPC ensures the implementation of pharmacovigilance 
in health institutions by providing medical practitioners with the necessary trainings for the 
implementation of this practice. Also, it is within the jurisdiction of the Centre to ensure 
serious monitoring, assessment and improvement of public health programs for the health 
and safety of the general public.  Amongst the six aspects that must be addressed for public 
health programs to succeed, Frieden (2014) asserted that performance management which 
includes critical monitoring, assessment and improvement must be seriously considered.  This 
shows the necessity of the monitoring factor in the subject matter of pharmacovigilance. 
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Finally, the NPC is in charge of monitoring and controlling its pharmacovigilance centres in 
the six zones of the country. The NPC through its zonal centres authorises organisations, profit 
or non-profit to market specific pharmaceutical products. These organisations are referred to 
as “market authorisation holders” (MAHs). Once these pharmaceutical products are 
marketed and are being used by patients, the market authorisation holders remain 
responsible for monitoring the safety of these products. At any time, adverse reactions from 
patients’ use of these products are observed or suspected, these organisations are required 
to report to the NPC for appropriate actions.  
2.6 ADR MONITORING BY NAFDAC 
As earlier stated, the monitoring of ADRs to a large extent depends upon the rate of reporting. 
The National Agency for Food and Drug Administration and Control has been faced with issues 
challenging its effective monitoring of pharmaceutical products in the country which majorly 
points to the low rate of reporting in the nation. Awodele et al. (2018) consented to this by 
stating that, a flawless ADR monitoring practice for safety in the use of pharmaceutical 
products is consequent upon a robust system put in place for ADR reporting. Ibrahim Ali, the 
acting director of the pharmacovigilance/post marketing surveillance also concurred to this 
by revealing that adverse drug reactions reporting is a responsibility that should be taken 
seriously because if there are no reports, there can be no documentation for effective 
monitoring practice (Premium Times, 2016). This has caused NAFDAC to partner with medical 
institutions and other stakeholders for the obtaining of relevant ADR data in order to make 
effective the monitoring system for safe use of drugs or medicines in the nation.   
Given the necessity for the monitoring of drug safety as revealed in the National Drug Policy, 
a need for the formulation of a national pharmacovigilance policy was seen as a priority by 
NAFDAC (Nwokike, 2008). The rationale behind the formulation of this policy is to ensure an 
excellent pharmacovigilance system that allows for rational and safe use of pharmaceutical 
products in the nation. The national pharmacovigilance policy reveals the roles every actor 
has to play in monitoring the safety of medical products. According to this policy, to achieve 
a better vigilant medical society, there is the need for setting up fixed monitoring and 
examination frameworks for measuring the performance and impact of authorised drugs 
already available in the market.   
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Nwokike (2008) further revealed some factors inhibiting the effective monitoring of ADRs by 
NAFDAC in Nigeria. According to him, the low rate of ADR reporting in the nation is one factor 
that cannot be put out. The agency can only monitor the safety level of drugs when ADR cases 
are detected, adequately documented and reported. However, Nwokike (2008) opined that 
the complexity of the ADR report forms makes it difficult for medical practitioners who are 
the principal actors in the detecting, documenting and reporting of cases to do so. Their busy 
schedules do not allow them the time to fill the complex forms provided for ADR reporting. 
Frieden (2014) opposed the complexity of these ADR forms by stating that simplicity is a major 
key to any successful endeavour. Another factor hindering the effective monitoring of ADRs 
by NAFDAC is the poor collaboration between the agency and public health programs in the 
nation. Public health programs are implemented to prevent or control diseases and even 
death. The partnership of NAFDAC with public health programs will improve ADR monitoring 
by aiding the setting up of adequate systems for data collection, evaluation of causality, and 
the carrying out of further pharmacovigilance studies using the ADR reports generated from 
the public health programs.   
2.6.1 FACTORS THAT HINDER NAFDAC FROM EFFECTIVE IMPLEMENTATION OF ADR 
MONITORING IN NIGERIA 
Having reviewed several literatures, some factors that inhibit the successful implementation 
of ADR monitoring by NAFDAC in Nigeria have been identified. In Nigeria, the reporting of 
ADRs has been made voluntary for medical practitioners but compulsory for market 
authorisation holders. This is an aspect that should be reviewed in order to improve the 
monitoring of ADRs by the regulatory agency. The reporting of ADRs should be a mandatory 
activity for every practitioner/institution in the medical sphere and not relegated to just a 
few. Although the amount of reports in the database of NPC has increased to 16,222 reports 
within the period of September 2004 and May 2015 and about 11,000 reports have been 
transmitted to the international database of the WHO (vigibase), this does not justify an 
improvement in the monitoring process because the WHO standard requirement of 200 
reports per million population is yet to be attained in the nation (Olowofela, Fourrier-Réglat 
and Isah, 2016).  
Varallo et al. (2014) in their study titled, “causes for the underreporting of adverse drug 
events by health professionals: A systematic review” showed that the major causes of the low 
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rate of reporting were ignorance, insecurity and indifference. They stated most medical 
practitioners are not aware of the significant role ADR reporting plays in safeguarding the 
health of patients and also are afraid of litigation matters that could ensue from the practice. 
This finding aligns with that of Ezeuko, Ebenebe, Nnebue and Ugoji (2015) who revealed that 
most of the medical professionals in the nation are unaware of the ADR reporting process and 
as a result lack interest in the activity. Furthermore, the complexity involved in the ADR 
reporting process is another factor that contributes to the high rate of under-reporting in the 
nation and thereby affecting the level of ADR monitoring. 
Further to the foregoing, some other factors seem to contribute to the ineffective monitoring 
of ADRs by the NAFDAC. Olowofela, Fourrier-Reglat and Isah (2016) identified poor 
infrastructural facilities, lack of qualified manpower and poor support from government to be 
some factors affecting pharmacovigilance in the nation. Nwokike (2008) also revealed that 
the lack of collaboration between NAFDAC and public health programs is one of the factors 
inhibiting effective monitoring system in Nigeria. Also, Akunyili (2010) spotted out other 
factors negatively affecting drug regulation by NAFDAC in the country. According to her, 
corruption and conflict of interest has been a factor affecting regulation of drugs in the nation. 
Many fake drugs have been allowed into the Nigerian market due to compromise by 
inspection personnel. Outside compromise by inspection personnel, many importers have 
declared falsely the contents of their containers. Investigations in time past have revealed 
that some of these importers hide fake drugs in different goods like household items, motor 
spare parts, clothes, etc and pushed them into the market for public consumption. She further 
revealed that the poor judicial process and legislation is another factor that inhibits the 
progress of the agency in regulating drugs in the nation. The existing laws against fake drugs 
are so lenient that defaulters do not see it as a threat to their inhumane activities. These, 
amongst others have been issues that make NAFDAC seem ineffective in the dispensation of 







2.7 NAFDAC’s ACTIVITIES IN POST-MARKET SURVEILLANCE FOR LOCALLY PRODUCED 
DRUGS 
Nigeria has always been known to be a consuming nation and this reflects in almost every of 
its sector. In the health sector for instance, about 60 percent of the drugs consumed in the 
nation are imported from other nations especially from China and India (Akunyili, 2010). This 
implies that about 40 percent of drugs consumed in the nation are locally produced. This calls 
for the drug regulatory agency under the ministry of health, NAFDAC to ensure the drugs 
available in the market are safe for public consumption.  
The process whereby NAFDAC collects data primarily on the safety of drugs or pharmaceutical 
products already marketed is simply referred to as post-market surveillance. In discharging 
its duties, NAFDAC has implemented several processes to ensure the drugs locally produced 
are safe for use by the general patient population. Some of these processes include 
inspection, drug or pharmaceutical product registration, enforcement, public awareness, and 
adoption of modern technologies (Pharmapproach, 2020).  
As part of the inspection process, NAFDAC ensures post-market surveillance is done in 
accordance with the WHO guidelines and initiate predetermined actions for eradicating fake 
drugs already available in the market. Moreover, the regulatory agency, after inspection of 
local factories at the initial time of product registration, still goes ahead to inspect them 
without prior notice once in every three months. The reason for this impromptu inspection is 
to ensure the local factories keep up with the Good Manufacturing Practice (GMP) which 
initially guaranteed their product registration. Good Manufacturing Practice (GMP) is simply 
a practice that ensures that products are consistently produced and controlled in accordance 
with predetermined quality standards (WHO, 2020). Despite the so-called routine inspection 
exercise, the impact of this exercise is yet to be felt in the nation.  
Concerning drug or pharmaceutical product registration, NAFDAC ensures local factories 
responsible for the manufacturing of these medical products are certified in accordance with 
WHO qualifications before being registered. However, one big question is, many of the drugs 
registered and authorised into the market for public use, have they all been safe? This is a 
question that requires both an answer and a solution.  
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Furthermore, as regards enforcement which has to do with the investigation of cases, criminal 
prosecution, partnering with formal and informal groups, carrying out of surveillance 
activities to tackle benefactors of the business of fake drugs in the nation, NAFDAC has made 
a bit of success. Several fake drug dealers over the years have been prosecuted and such drugs 
outlawed and banned from the market. This in a way has contributed to the safety of the 
entire public. To further ensure the availability of quality drugs in the market, NAFDAC went 
ahead to create an improved drug distribution network for easy and effective monitoring. 
Despite this effort, selfish ambitions amongst stakeholders (of which members of staff of 
NAFDAC are inclusive) have disallowed the effectiveness of the aspect of enforcement in 
Nigeria.   
Moreover, NAFDAC is authorised under section 14 of the National Agency for Food and Drug 
Administration and Control Act, Cap N1, Laws of the Federation of Nigeria (LFN) to utilise its 
financial, human and material resources to publicise its activities. Over the years, NAFDAC has 
conducted awareness campaigns on fake drugs to almost every part of the society, partnered with 
relevant stakeholders like the Nigerian Drug Law Enforcement Agency (NDLEA), Consumer Protection 
Council of Nigeria (CPCN), the Nigeria Police, etc in enlightening the public on how to identify 
fake drugs in the market.  
Finally, one other measure adopted by NAFDAC in post-market surveillance is the use of 
recent technology in the detection of fake drugs in the market. Technologies such as TruScan, 
a mobile device used for detecting fake drugs at an instant recently developed by the US 
military, The Mobile Authentication Service (MAS), a system that aids the detection of fake 
drugs through the use of a cell phone. It involves the texting of a code placed on the packet 
of the drug right from the point of manufacture through the use of SMS. After which, a 
message confirming the originality or non-originality of the product is received. These, 
amongst others are the technologies employed by NAFDAC in ensuring drugs available in the 
market are safe for public use.  
2.8 ADR MONITORING IN KENYA 
Since 2004, the Pharmacy and Poison Board’s (PPB), the regulatory authority instituted under 
the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya, initiated the process of ADR 
monitoring in Kenya in which led to the official launching of the National Pharmacovigilance 
System in the nation five years later. The principal aim behind the launching of this system 
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was to ensure the safety of patients in the use of drugs. Since then, the monitoring of adverse 
drug reactions in the nation has experienced different bottlenecks in the effective 
implementation of the practice. The reporting of adverse reactions has been manually done 
with the aid of printed forms; yellow forms for reporting of suspected ADRs and pink forms 
for reporting of low-quality medicines.  
The manual process which characterised the use of printed forms was cost intensive and time 
consuming. The printed forms have to first be transported to all medical institutions in the 
country, ensuring every unit in these institutions are in possession of the forms. Also, to get 
the feedback, the same process is entailed. This rigorous process characterised the ADR 
monitoring system in Kenya for over three years.  And therefore, not so much was achieved 
in eradicating low quality and poisonous drugs from the nation.  
However, on April 13, 2013, Kenya took to a new leaf by digitising the ADR monitoring system 
in the nation. This was believed to make the entire process easier, faster and less cost 
intensive. Since the implementation of the digital ADR monitoring system in the nation, there 
has been increased effectiveness and efficiency in the monitoring process. The PPB has been 
able to receive more than 6000 adverse reaction reports and more 370 reports of low 
standard medicines which has geared up the withdrawal of these medicines from the market 
and shut down of pharmaceutical companies that did not meet up to the standard 
requirements. The rise in reported cases was affirmed by Barry et al. (2020) in their 
comparative study revealed that Kenya pharmacovigilance centre had received the highest 
number of safety reports, showing 35.0 per million residents amongst the four countries. 
Otieno in 2013 explain that the launching of this monitoring system made Kenya become the 
first nation both in Africa and the world that utilised mobile technology to digitise reporting 
for ADR monitoring. 
2.9 COMPONENTS OF AN IDEAL ADR MONITORING SYSTEM  
An ADR monitoring system is termed to be ideal for use by a regulatory body if it possesses 
some elements that aid the effective monitoring of adverse reactions of drugs by the general 
patient population in the nation. As aforementioned, Yadav (2008) was of the viewpoint that 
an ADR monitoring system must include collection of data from medical practitioners, 
classification and assessment of collected data and dissemination of outcome on inspected 
drugs to all health sectors and the general public.  According to him, it is implied that report 
39 
 
collection, report analysis and outcome are the major components of an ADR monitoring 
system. Patidar et al. (2013) supported the need for the localisation of the monitoring practice 
in every hospital. According to them, every hospital needs to engage in monitoring the 
adverse reaction of drugs on patients and submit obtained data to the regulatory authority. 
This implies the need for the enforcement of the monitoring practice in every medical 
institution. They further established that emphasis on public education against self-
medication, training of medical practitioners and the inclusion of ADR in the curriculum of 
medical students should comprise an ideal ADR monitoring system. Nwokike (2008), on the 
other hand stated that a good ADR monitoring system should have a simplified and digitised 
reporting system for every level of medical care delivery, establish safety indicators for drugs 
and provide trainings.    
To buttress further, given the fact Nigeria is a developing nation and looks up to the developed 
nations, there is a lot that can be gleaned from the European Medicines Agency (EMA) as 
regards components of an ideal monitoring system. The European Medicines Agency (EMA) 
is the regulatory authority responsible for the coordination of pharmacovigilance activities in 
the European Union (EU). It comprises certain components that allows for its effective 
functioning in the EU. Its components include the Pharmacovigilance Risk Assessment 
Committee (PRAC) which is responsible for the evaluation and monitoring of drugs safety in 
the continent; the EudraVigilance, a database for the storage of suspected ADR reports in the 
EU; the research unit which seeks for ways through which pharmacovigilance activities can 
be improved; and an evaluative framework that constantly reviews the progress of 
pharmacovigilance activities with the aim to redirect actions that can further improve the safe 
use of drugs on/by patients.  
2.10 Network Governance Theory 
Over the years, the term “network governance” have been labelled with different terms. 
Miles and Snow (1986) referred to it as “network organisation”, Eccles (1981) called it “quasi-
firms”, Piore and Sable (1984) in their opinion, named it “flexible specialisation”, Liebeskind 
et al. (1996) referred to it as social networks. These have all been used to mean the 
synchronisation of different firms that involves informal relationships or interactions as 
against bureaucratic frameworks within firms and formal contractual associations between 
them. Jones, Hesterly, and Borgatti (1997) defined it as a given set of independent firms 
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working repeatedly together as a sequence of exchange aided by a network structure in the 
creation of products or services founded upon implicit and open-ended contracts that are 
socially and not legally binding to acclimatise to environmental contingencies and to 
coordinate and safeguard exchanges. It is important to note that legal contracts are not the 
basis of relationship in this this theory but social contracts.  
The Network Governance Theory simply states that for complex and uncertain problems to 
be solved, concerned individuals or institutions need to form policy networks of different 
expertise where the networked relationship is socially and not legally binding. This theory is 
relevant to this study because it aids in the explanation of how and why NAFDAC, the drug 
regulatory agency in Nigeria should partner with relevant stakeholders both locally and 
globally in the monitoring of adverse reactions of drugs released into the market for medical 
use by patients. Network Governance Theory is very pivotal to the practice of 
pharmacovigilance in Nigeria because it allows for the creation of a network of relevant social 
partners who would contribute to the policy making process for the safety of the general 
patient population. The practice of pharmacovigilance is moulded by a network of local and 
international partners who have direct or indirect influence on the way the practice is carried 















CHAPTER THREE: RESEARCH METHODOLOGY 
3.1 INTRODUCTION 
Research methodology is simply referred to as the techniques or methods adopted in the 
analysing a research problem. This chapter is concerned with the methods adopted in the 
investigative process of the study. It focuses on the research design, research philosophy, 
methods of data collection and analysis, ethical considerations, validity and reliability of 
research instrument, etc.  
3.2 RESEARCH APPROACH 
This study adopted the use of quantitative method through the aid of electronic survey 
questionnaires in obtaining data for the study. The justification for adopting the quantitative 
approach in this study is the space it does not allow for subjectivity and bias and the provision 
it makes for the generalisation of findings on a wider population. The objectivity of 
quantitative method allows for conclusions to be based solely on facts and not biases of the 
researcher. The electronic questionnaires were distributed to staff members of NAFDAC who 
the target participants for the study were. This prompted the gathering of suitable data for 
statistical analysis. Findings obtained from the analysis of data collected were compared with 
findings of previous researches to ascertain the position of the researcher on the given study. 
3.3 RESEARCH METHODS 
Consequent upon the quantitative nature of this study, the research method adopted is the 
descriptive research method. A descriptive research is primarily one that deals with the 
description of a given phenomenon the exact way it is without any interference. It simply 
involves explaining the state of affairs of a given phenomenon without any external influence 
on the variables of the research. It is usually concerned with studies that seeks to identify or 
explain facts.  
3.4 RESEARCH PHILOSOPHY 
This study is premised upon the research philosophy of positivism. The reason for the 
adoption of this philosophy is consequent upon the quantitative nature of the study. 
Positivism is of the ideology that only factual knowledge derived from observations using 
measurement are reliable and it is in tandem with empiricist view that knowledge is an 
42 
 
outcome of human experiences. This philosophy of positivism limits the researcher to collect 
data and interpret it objectively and research findings are observable and quantifiable. 
The electronic survey questionnaires were administered to staff members of NAFDAC to 
obtain data for objective analysis and interpretation. The study was free from the interference 
or individual bias of the researcher but was based solely on observed facts. This is one 
advantage the positivist ideology provides for a credible research study – freedom from 
individual bias and influence. This position on objectivity in the analysis and interpretation of 
data was obtained by the administration of electronic survey questionnaires to the study’s 
participants.  
3.5 STUDY AREA & STUDY POPULATION 
The study area refers to the geographical area in which the research instrument was 
administered for the purpose of collection, analysis and interpretation of data. The study area 
used for this study is the NAFDAC Lagos Operational Office located at Plot 1, Industrial Estate, 
Lagos, Oshodi-Apapa Expressway, Isolo, Lagos, Nigeria. The justification for the selection of 
this study area is the easy accessibility to participants due to the researcher’s relationship 
with the gatekeeper of this research site.  
Study population on the other hand simply refers to a given population apportioned for 
examination. Ngechu (2004) defined it as a set of people, services, elements, group of things 
or households under examination which have a definite set of characteristics.  Moreover, 
these participants are chosen based on the responsibility NAFDAC holds in coordinating the 
activities of pharmacovigilance in Nigeria through the arm of the NPC.  
3.5.1 ELIGIBILITY CRITERIA 
Pilot and Hungler (1999) defined eligibility criteria as those features participants in a study 
must possess in order to be included in the study. For participants to be included in this study, 
they had to be staff members of NAFDAC Lagos Operational Office, which is situated at Plot 






3.6 SAMPLING PROCEDURE 
Sampling is simply referred to as the process or technique of choosing an appropriate sample, 
or a representative part of a population in order to determine the features of the entire 
population (Mugo, 2002). A number of the staff of NAFDAC Lagos Operational Office was 
selected to represent the entire population of NAFDAC staff in the country. Due to the use of 
a sample, time and money were conserved. Instead of attempting to investigate the entire 
staff of NAFDAC nationwide, a few was just selected to represent the entire population. Given 
the little time to complete this study, collecting, analysing and interpreting data from the 
entire staff of NAFDAC nationwide would have been a herculean task to achieve and would 
have become financial burdensome for the researcher to carry out.  
3.6.1 PROBABILITY SAMPLING 
A probability sampling is simply a sampling method that requires a researcher to select 
samples from a larger population using techniques premised upon the ideology of probability. 
In aiming to achieve this study’s objectives, the type of probability sampling used was the 
simple random sampling method. A simple random sampling method is one that provides 
every item or member of a given population with an equal chance to be selected in a sample. 
This method was chosen because it creates room for findings obtained to be generalised on 
the entire population.  
3.6.2 SAMPLE SIZE DETERMINATION 
Sample is a subgroup of the population to be examined. It is simply a subset of the composite 
whole of a given population under study. Sample size determination on the other hand refers 
to the process of selecting a given number of items or members to be included in a statistical 
sample. In research, it is common knowledge that the larger the sample size, the more 
accurate the results and the more credible the study. Smaller sample size is believed to 
generate less accurate results due to the fact they are of lesser representation on the entire 
population.  
To determine the sample size for this study, Cochran’s (1963) formula was adopted. The 
reason for the adoption of this formula is the uncertainty in the precise number of the study’s 
population. Using the Cochran’s (1963) formula, the sample size determination can be 





n = Z2 pq 
         e2 
 
Where: 
e = the desired level of precision (i.e. the margin of error) = 0.05 
p = the (estimated) proportion of an attribute present in the population = 0.9 
q = 1 – p  
= 1 – 0.9 = 0.1  
Z = 1.96 
n = (1.96)2 x 0.9 x 0.1 
 (0.05)2 
 
n = 3.8416 x 0.9 x 0.1 
 0.0025 
 
n = 0.345744 
        0.0025 
 
n = 138.30 
 
n = 138 (sample size) 
 
 
However, given the proposition of Israel (1992), an additional percentage should be given to 
the generated sample size in order to cover up for the non-response of respondents. As a 
result, an additional 10 percent was added to the generated sample size of 138 which led into 
the study’s sample size of approximately 152. This can be mathematically expressed below 
as: 
n = 138 x 10% = 13.8  
n = 138 + 13.8 = 151.8  





3.7 METHODS OF DATA COLLECTION 
In carrying out this study, primary research was used. This called for the collection of data 
directly from participants. Data was collected with the use of electronic survey 
questionnaires. The rationale behind the use of electronic survey questionnaire is the time, 
cost and stress saving nature of the research instrument. The questionnaire link was 
forwarded to the gatekeeper of the study area which in turn forwarded this link to the 
participants. Adequate attention and follow-up were paid to the gatekeeper to ensure the 
required number of participants for the study gets access to the questionnaire.  
3.7.1 RESEARCH INSTRUMENT 
This study made use of a close-ended electronic survey questionnaire in obtaining data from 
its participants. A close-ended questionnaire is one that limits respondents to only the options 
made available by the researcher. In this type of questionnaire, participants are not given the 
freedom of expression in responding to the questionnaire items.  
Questionnaires were administered to participants electronically using the platform, Microsoft 
Form. The questionnaire comprised five sections which are: one, the section relating to the 
socio-demographic characteristics of the respondents; two, the section relating to 
respondents’ perceptions on NAFDAC’s capability to monitor and address ADR issues; three, 
the section concerned with respondents’ views on factors hindering effective ADR 
monitoring; four, the section proffers solution to help boost ADR monitoring;  five, the section 
relating to respondents’ perceptions about public health safety. A total of 20 questionnaire 
items were given in the research instrument. Five (5) belonging to the first section, eleven 
(11) belonging to the second section, one (1), which involves multiple answers belonging to 
the third section, five (5) belonging to the fourth section and four (4) belonging to the last 
section. 
From the fourth section to the fifth section, questions were presented on a 5-point Likert 
scale. The reason for the use of a 5-point Likert scale format is to increase response rate and 
quality according to Sachdev and Verma (2004). Given the 5-point Likert scale format, all the 
variables of a set were assigned specific numerical values. For instance, Strongly Agree (SA) 
was assigned a value of 1, Agree two (2), Undecided three (3), Disagree four (4), Strongly 
Disagree five (5). 
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3.7.2 VALIDITY OF THE RESEARCH INSTRUMENT 
 According to Srinivasan and Lohith (2017), Validity of a research instrument is simply the 
degree to which a tool measures what it was designed to measure. Heale and Twycross (2015) 
defined it as the level to which a concept is correctly measured in a study of quantitative 
nature. In the words of Sullivan (2011), validity of a research instrument is described as the 
degree to which a research study provides answers or solutions to a research question(s). 
Validity, in summary, has to do with the credibility of conclusions derived from a research 
study.  
In carrying out this study, face validity and content validity were used to ascertain the 
credibility of the research instrument. Odetunde (2011) explained that face validity has to do 
with whether the questions in a research instrument truly measures what it was designed to 
measure. Content validity on the other hand is used to determine if the instrument covers 
relevant contents with respect to the topic’s variables. By using face and content validities, 
the researcher submitted the questionnaire to his supervisor to critically scrutinise and give 
better opinions on how the research instrument can be further modified to improve its 
credibility.  
To further ensure validity of the research instrument, a pilot study was conducted. A pilot 
study is simply a mini-investigative process in which research instruments are administered 
to a small number of participants in order to ascertain the validity of the instruments. Pilot 
study was done in this study to generate the time that would be taken to complete the 
questionnaire and to receive feedback on the clarity of questions in the research instrument 
for the aim of modifying it to generate credible conclusion. In piloting this study, ten (10) 
questionnaires were administered to some staff members of NAFDAC Lagos Operational 
Office.  
3.7.3 RELIABILITY OF THE RESEARCH INSTRUMENT 
Reliability of a research instrument is concerned with the consistency of the results 
generated. A research instrument is termed to be reliable if the result it generates are 
repeatable. To ascertain the reliability of this study’s instrument, the researcher made use of 
the Cronbach’s alpha coefficient. A Cronbach’s alpha coefficient is a convenient test used to 
measure the internal reliability of a composite score. Sekeran (2003) stated that the closer 
the Cronbach’s alpha coefficient is to 1, the more reliable it is. According to Oyeniyi et al. 
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(2016), a Cronbach’s alpha coefficient should be accepted if its value is at 0.8 or above. They 
further opined that Cronbach alpha is an appropriate test for questionnaires with the Likert 
scale format. Hinton, Brownlow, McMurray and Cozens (2004) in their view asserted that a 
Cronbach’s alpha coefficient should be accepted as a moderately reliable scale if it ranges 
between 0.5 and 0.75.  
3.8 METHOD OF DATA ANALYSIS 
Data collected from the field survey was analysed with the use of the Statistical Package for 
Social Sciences (SPSS) version 20.0 using descriptive statistics. The rationale for choosing the 
SPSS for data analysis is because it provides a wide range of statistical options. Results 
generated were presented in frequencies and percentage in tables, pie charts and bar charts. 
The two hypotheses of the study were tested using simple linear regression analysis and Karl 
Pearson’s correlation methods. The simple linear regression analysis is usually used to test 
the impact of an independent or predictor variable on a dependent or outcome variable while 
correlation is simply used to test the degree of relationship that exists between two variables. 
3.9 ACCESS & ETHICAL CONSIDERATION 
It is a well-known fact in the field of research that ethical issues are of paramount concern. 
When conducting a research study, adequate attention should be paid to ethical issues like 
confidentiality, informed consent, anonymity, etc (Creswell, 2005). In carrying out this study, 
access and ethical considerations were strictly adhered to. To all participants of the study, the 
study’s topic was briefly explained and were all duly informed of the study being a pure 
academic exercise for the attaining of a master’s degree. Participants were given the freewill 
to decide to participate in the study or not, were duly informed about keeping their identities 
hidden and information confidential and were also informed of no financial involvement if 
they decided to participate. Every participant who took part in this study, did so willingly. 
3.10 CONCLUSION 
Conclusively, this study made use of only the quantitative approach with the aid of close-
ended electronic survey questionnaires which comprised 20 questions. And these 
questionnaires were distributed to a sample size of 152 staff member of NAFDAC Lagos 
Operational Office. The study is built upon the epistemological approach of positivism which 
advocated for the use of objective means in the observation of facts. Data obtained from the 
participants were analysed and compared with previous findings of other researchers. The 
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researcher aimed at determining if NAFDAC possesses the capability to monitor and address 
reported ADR cases, to identify the limiting factors of NAFDAC’s effective ADR monitoring for 




CHAPTER FOUR: DATA ANALYSIS AND FINDINGS 
4.1 OVERVIEW 
This chapter is concerned with the collection, analysis and interpretation of data and 
presentation of study’s findings in a way that is understandable to its readers. It is in this 
chapter, answers to the study’s questions are given. The quantitative information obtained 
from this chapter helped the researcher to ascertain if NAFDAC possesses the capability to 
monitor and address reported ADR cases, to identify the factors that hinder NAFDAC from 
effectively monitoring ADR in Nigeria and to proffer solutions that will aid in boosting ADR 
monitoring in NAFDAC. 
4.2 Demographic Data  
4.2.1 Response Rate: 
The research questionnaire was administered to a total of 152 respondents who are staff of 
NAFDAC, Lagos Operational Office. In the administration of the survey questionnaire, only 
139 respondents participated and gave acceptable responses. This means the study had a 
response rate of 91%. 
Out of the 139 respondents who participated in the study, 55.4% were male, 42.4% were 
female while 2.2% refused to disclose their gender. This result shows that most of the 
respondents who participated in the study were male implying more male are employed in 
the Agency than their female counterpart.  
4.2.2 Age of Respondents: 
Concerning the age of respondents, 35.3% were between the ages of 18 and 30 years, 36.7% 
were between the ages of 31 and 40 years, 12.9% were of the ages 41 and 50 years, 11.5% 
were between the ages of 51 and 60 while just 3.6% are of the age of 61 years or above. From 
this analysis, it is seen that most of the respondents who participated in the study are 
between the ages of 31 and 40 years implying a majority of the staff being within that age 
range. 
4.2.3 Level of Education 
As regards respondents’ level of education, only 0.7% had no formal education, 40.3% had a 
graduate level of education while 59.0% had a postgraduate level of education. This implies 
that most of NAFDAC staff have a postgraduate level of education since a majority of the 
respondents indicated they had a postgraduate education.  
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4.2.4 Level in the Firm 
With respect to level in the firm, 16.5% of the respondents are at the entry level, 35.3% are 
at the mid-level, 39.6% are at the senior level while 8.6% are at the management level. This 
analysis shows that staff at the senior level participated most in the study. 
4.2.5 Employment Duration 
Concerning employment duration, 22.3% of the respondents indicated that they have been 
working with the firm for the past two years, 33.1% revealed they have been working with 
the firm within the range of 3 and 5 years while 44.6% showed that they have been working 
with the firm for more than five years. This shows that most of the respondents who 
participated in the study have been working with the firm for more than five years. 
Demographics Frequency 
(139) 
Response Rate (%) 
Gender 
Male 77 55.4 
Female 59 42.4 
Prefer not to say 3 2.2 
Age (years) 
18-30 49 35.3 
31-40 51 36.7 
41-50 18 12.9 
51-60 16 11.5 
61 and Above 5 3.6 
Level of education 
No formal education 1 0.7 
Undergraduate 56 40.3 
Postgraduate 82 59 
Level in the firm 
Entry level staff 23 16.5 
Mid-level staff 49 35.3 
Senior level staff 55 39.6 
Management staff 12 8.6 
Employment duration 
0 – 2 Years 31 22.3 
3 – 5 Years 46 33.1 
Above 5 Years 62 44.6 
ii Table 4.1: Demographics Data of Respondents 
Source: Field Survey (2020)  
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4.3 Capacity to Monitor and Address Reported ADR Cases (Questions 7 – 17)  
This section revealed the respondents’ views on whether NAFDAC has the capacity to monitor 
and address reported ADR cases in the nation.  
Question 7: 
In the analysis of respondents’ understanding of ADR monitoring, 38.8% indicated that they 
understand ADR monitoring extremely well, 31.7% revealed that they understand ADR 
monitoring not too well. 14.4% showed indifference to the question, 11.5% revealed that they 
somehow do not understand what ADR monitoring all is about while 3.6% showed that they 
do not understand ADR monitoring well. See Figure 6 
 
Figure 6: Knowledge of How Well Staff Understand ADR Monitoring 
As shown in Figure 6 above, most of the staff revealed they really understand what ADR 
monitoring is about. This means that NAFDAC has staff who are knowledgeable enough to 
effectively carry out ADR monitoring in the nation.  
Question 8:  
Concerning respondents being well provided with the required equipment for active ADR 
monitoring, 44.6% selected the “yes” option, 42.4% selected the “no” option while 12.9% 




Figure 7: Knowledge of whether the Required Equipment for Active ADR Monitoring Are Well Provided 
As depicted by Fig. 7 above, a majority of the staff revealed that they are well provided with 
the needed equipment for active ADR monitoring. The provision of needed equipment 
contributes to the agency having the capability to monitor and address ADR cases.   
Question 9: 
To ascertain if adverse drug reactions reports have been monitored by staff in the past 12 
months, 44.6% of the respondents said “yes”, 50.4% said “no” while 5% were not aware. From 
this analysis, it is seen that most of the staff have not monitored adverse drug reactions 
reports for the past 12 months. This could be a reason why ADR monitoring is low in Nigeria 
if just a few members of staff of the regulatory agency have monitored ADR reports in the 




Figure 8: Knowledge of Whether Adverse Drug Reactions Reports Have Been Monitored in the Past 12 Months 
Question 10:  
Concerning the issue of there being a reliable database for the storage of reported ADR cases, 
52.5% of the respondents positively responded by ticking “yes”. 25.2% ticked “no” while 
22.3% showed they do not know. – See Figure 9 below: 
As shown in the figure below, it is quite obvious that a greater population of staff admitted 
that there is reliable database for the storage of reported ADR cases. This shows the agency 
has one of the required assets needed for effective ADR monitoring in the nation. 
 
Figure 9: Graphical Representation Showing Whether a Reliable Database for the Storage of Reported ADR Cases Exists 
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Question 11:  
Based on the previous question, in analysing how often is the database for ADR reports 
updated, 20.1% indicated the database are often updated weekly, 23.7% showed that it is 
updated monthly, 39.6% indicated that it is updated quarterly, 4% stated it is updated 
annually while 13.7% showed that it was never updated. – See Figure 10
 
Figure 10: Graphical Representation of How Often the Database for ADR Reports is Updated 
Based on the data provided above, the updating of ADR reports quarterly is not encouraging 
for an effective ADR monitoring system. ADR reports being updated quarterly means the 
reports are not updated on the database until another three months. This tends to drag or 
slow down monitoring by the agency.  
Question 12 
In order to identify if staff often get trained on better ADR monitoring practice, 38.1% 
indicated “yes” while 61.9% ticked “no”. The survey results show that most staff are not 
trained often on better ADR monitoring practice. Since more than half of the staff in the 
agency refuted that they are frequently trained on better ADR monitoring practice, it means 









Question 13:  
As regards there being a good communication network between staff and other relevant 
stakeholders, 44.6% gave a positive response of “yes”, 24.5% gave a negative response of 
“no” while 30.9% indicated they were unaware. – See Fig. 12 
 
Figure 12: Graphical Representation Showing Respondents’ Views on Whether a Good Communication Network Exists 
between Staff and Other Relevant Stakeholders. 
As evidenced from the above figure, most of the staff have a good communication network 
between themselves and other relevant stakeholders. This is an advantage for the agency to 
perform better when it comes to monitoring ADRs in the nation.  
Question 14: 
In ascertaining whether the agency have a strong network of partners which help in the 
collection, reviews and reports of ADRs, 48.2% of the respondents indicated “yes”, 19.4% 
indicated “no” while 32.4% revealed they are unaware. It can be seen from this analysis that 
a majority of staff admitted that the agency has a strong network of partners that assists in 
the collection, review and reports of ADR. This means that the agency has the required 




Figure 13: Graphical Representation Showing Respondents’ Views on Whether the Agency Have a Strong Network of 
Partners That Aids in the Collection, Reviews and Reports of ADRs 
Question 15: 
To show whether there are sufficient laboratory facilities for further scientific assessment of 
ADR related drugs, 52.5% said “yes”, 28.1% said “no” while 19.4% revealed they are unaware. 
As seen in this analysis, a higher percentage of staff admitted that there are enough 
laboratory facilities for further scientific assessment of ADR related drugs. Of course, the 
scientific examination of drugs needs sufficient equipment to be able to provide accurate 
results for decision-making. This can be graphically represented in Figure 14 below: 
 
Figure 14: Graphical Representation Showing Whether There Are Sufficient Laboratory Facilities for Further Scientific 




Concerning having an idea of the necessary actions required after an ADR related drug is 
discovered/reported, 64% revealed that they do have an idea, 14.4% indicated they do not 
have an idea while 21.6% could not decide if they had an idea or not. Below is a graphical 
representation of respondents’ views: 
 
Figure 15: Graphical Representation Showing If Staff Have an Idea of The Necessary Actions After an ADR Related Drug Is 
Discovered/Reported. 
As depicted by figure 15, most of the staff reported that they are aware of the necessary 
actions to be carried out when an ADR related drug is discovered/reported. This tallies with 
previous finding on question 6 which showed that most of the staff are well aware of ADR 
monitoring practice.  
Question 17: 
As regards there being a well-designed program to educate medical practitioners and 
consumers on ADRs, 48.2% gave a positive response of “yes”, 18.7% gave a negative response 




Figure 16: Knowledge on Whether a Well-designed Program for the Education of Medical Practitioners and Consumers on 
ADRs 
Most of the staff admits that there exists a well-structured activity for the education of 
medical practitioners and consumers on ADR. This calls for a better implementation process 
in order to achieve desired results.  
4.4 Factors Hindering NAFDAC from Effectively Monitoring ADRs in Nigeria  
Question 18: 
In identifying factors hindering NAFDAC from effectively performing ADR monitoring in 
Nigeria, different options were presented to respondents to choose from to reveal their 
perceptions on the issue. The researcher aimed at extracting factors from NAFDAC staff that 
have been limiting the agency from effectively monitoring drugs in the nation.  
49.6% of the respondents indicated that the lack of knowledge on monitoring practice of ADR 
is one of the factors hindering NAFDAC from effectively monitoring ADRs in Nigeria while 
50.4% refuted that.  
As regards poor and inconsistent training of staff on recent ADR monitoring development, 
66.2% gave a positive response of “yes” while 33.8% gave a negative response of “no”. It can 
be seen from this analysis that one of the factors hindering NAFDAC from effectively 
monitoring ADRs in Nigeria is poor and inconsistent training of staff on recent developments 
in ADR monitoring.  
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Moreover, 36.0% revealed that rigorous process in the collection, review and storage of ADR 
reports is a factor while 64.0% indicated that it is not a factor.  
Concerning inaccessibility to information stored on the Agency’s database, 36.0% gave a 
response of “yes” while 64.0% gave a negative response of “no”.  
With respect to absence of necessary laboratory equipment for scientific assessment of drugs, 
42.4% selected the “yes” option while 57.6% selected a “no” option.   
52.5% revealed that neglect for latest technological solutions is a factor hindering NAFDAC 
from effectively monitoring ADRs while 47.5% negated it.  
48.9% of the respondents showed that poor partnership between the Agency and relevant 
stakeholders is a factor limiting NAFDAC’s monitoring of ADRs while 51.1% opposed the 
statement.  
Concerning poor administration of the Agency, 51.8% admitted it as a factor limiting NAFDAC 
from effectively monitoring ADRs in Nigeria while 48.2% negated it. As regards corruption and 
conflict of interest, 61.2% gave a positive response of “yes” while 38.8% gave a negative 
response of “no”.  
Also, as regards the shortage of staff to properly monitor ADR and address ADR reports, 63.3% 
said “yes” while 36.7% said “no”.  
57.6% of the respondents gave a positive response to the questionnaire item of most 
healthcare professionals being afraid of legal issues while 42.4% gave a negative response of 
“no”.  
Finally, for this section, 69.8% of the respondents admitted that people do not report 




Factors Hindering NAFDAC 
from Effectively Monitoring 
ADRs in Nigeria  
Yes No 
Frequency Percentage Frequency Percentage 
Lack of Knowledge on the 
Monitoring Practice of ADR 
69 49.6 70 50.4 
Poor and inconsistent 
training of staff on recent 
developments on ADR 
monitoring 
92 66.2 47 33.8 
Rigorous process in the 
collection, review and 
storage of ADR reports 
50 36.0 89 64.0 
Inaccessibility to 
information stored on the 
Agency's database 
50 36.0 89 64.0 
Absence of necessary 
laboratory equipment for 
scientific assessment of 
drugs 
59 42.4 80 57.6 
Neglect for latest 
technological solutions in 
the monitoring of ADRs 
73 52.5 66 47.5 
Poor partnership between 
the Agency and relevant 
stakeholders 
68 48.9 71 51.1 
Poor administration of the 
Agency 
72 51.8 67 48.2 
Corruption and conflict of 
interest 
85 61.2 54 38.8 
Shortage of staff to properly 
monitor ADR and address 
ADR report 
88 63.3 51 36.7 
Most of the healthcare 
professionals are afraid of 
legal issues 
80 57.6 59 42.4 
People do not report 
experienced adverse drug 
reactions 
97 69.8 42 30.2 




4.5 Solutions That Will Help Boost ADR Monitoring by NAFDAC 
Consequent upon the factors identified by this survey as responsible for the ineffective 
monitoring of ADRs by NAFDAC, this section is geared towards proffering solutions that will 
aid NAFDAC to greatly improve in its monitoring operations of ADR-related issues in the 
country so as to safeguard the health of the general public. A great fraction of staff agreed 
with all the proposed solutions in the survey as being effective in the improvement of the 
level of ADR monitoring in Nigeria by NAFDAC. 
Question 19 (i – v): 
As regards the statement of staff being constantly trained in tandem with global best practices 
in the issue of ADR monitoring, 83.5% strongly agreed, 11.5% agreed, 2.9% were neutral while 
2.2% disagreed with no one strongly disagreeing. Cumulatively, 95.0% agreed while just 3 
2.2% disagreed. From this analysis, it can be deduced that staff should be constantly trained 
in alignment with global best practices with regards to ADR monitoring. Below is a graphical 
representation of respondents’ views:  
 
Figure 17: Graphical Representation Showing Respondents’ Views on Constant Training 
74.1% strongly agreed with the statement that staff need to be provided with necessary 
laboratory equipment for further scientific examination of drugs, 18% agreed, 5.0% were 
neutral, 2.2% disagreed while 0.7% strongly disagreed. Cumulatively, 92.1% agreed while just 
2.2% disagreed. This analysis shows that it is important for staff to be provided with the 






Figure 18: Graphical Representation of Respondents’ Views on the Need for Laboratory Equipment 
As regards there being an easy access to ADR data stored on the Agency’s database, 65.5% 
strongly agreed, 25.2% agreed, 7.9% were neutral while 0.7% each disagreed and strongly 
disagreed. Summarily, 90.7% agreed while just 1.4% disagreed. This connotes the need for 
staff to be granted easy access to ADR data stored on the Agency’s database. – See Figure 19 
below: 
  
Figure 19: Graphical Representation of Respondents’ Views on the Easy Access to Agency’s Database 
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Concerning NAFDAC adopting latest technological solutions in the monitoring of ADRs, 73.4% 
of the respondents strongly agreed, 19.4% agreed, 5.8% were neutral, 0.7% each disagreed 
and strongly disagreed. Summarily, 92.8% agreed while 1.4%) disagreed. This analysis 
indicates that adopting latest technological solutions in the monitoring of ADRs should be 
done by NAFDAC. – See Figure 20 below: 
 
Figure 20: Respondents’ Views on the Adoption of Latest Technological Solutions in the Monitoring of ADRs 
With respect to implementing a well-designed program for the education of medical 
practitioners and consumers on ADR issues, 74.1% strongly agreed, 19.4% agreed, 5.0% were 
neutral, while 1.4% disagreed with no one strongly disagreeing. This shows that 93.5% agreed 
with just 1.4% disagreeing. From this analysis, a well-designed program for the education of 
medical practitioners and consumers on ADR issues should be implemented. This can be 




Figure 21: Respondents’ Views on the Need for the Implementation of an Educational Program for Medical Practitioners and 
Consumers 
4.6 Public Health Safety 
This section is concerned with respondents’ views on how ADR monitoring could safeguard 
the health of the general public. This section consists of four (4) questionnaire items which 
shows how public health can be protected with the use of ADR monitoring. 
Question 20 (i - iv) 
In ascertaining if the addressing of ADR issues will drastically reduce deaths, 60.4% of the 
respondents strongly agreed, 29.5% agreed, 7.9% were neutral, 0.7% disagreed while 1.4% 
strongly disagreed. Cumulatively, 89.9% agreed while 2.1% disagreed. This analysis shows a 
greater percentage of staff admitting that addressing ADR issues will drastically reduce deaths 
implying the danger not addressing ADR issues pose to the safety of public health in the nation 




Figure 22: Respondents’ Views on Deaths being Reduced by Addressing ADR Issues 
Concerning the issue of effective ADR monitoring increasing safety in the use of drugs by the 
public, 62.6% strongly agreed, 30.2% agreed, 5.0% were neutral, 1.4% disagreed while 0.7% 
strongly disagreed. Summarily, 92.8% agreed while 2.1% disagreed. – See Figure 24 below: 
As shown in the figure below, almost all staff consented to the fact that effective ADR 
monitoring will increase safety in the use of drugs by the public. This shows that staff are fully 
aware of how crucial the practice of ADR is to the safety of lives.  
 
Figure 23: Respondents’ Views on Effective ADR Monitoring Increasing Safety in the Use of Drugs 
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With respect to the issue of ADR cases being reduced as ADR monitoring is intensified, 57.6% 
strongly agreed, 28.8% agreed, 9.4% were neutral, 4.3% disagreed with no respondent 
strongly disagreeing. Summarily, 86.4% of the respondents agreed while 4.3% disagreed. – 
See Figure 24 below: 
 
Figure 24: Respondents’ Views on ADR Cases being Reduced by the Intensifying of ADR Monitoring  
Based on the responses given by the survey, most staff indicated that ADR cases reduces 
when ADR monitoring is intensified. With this understanding, this means the rate of ADR 
cases is high since it is reported that the level of ADR monitoring is low in the nation. 
Finally, concerning the reduction in ADR cases showing the existence of an effective 
monitoring practice, 46.8% of the respondents strongly agreed, 37.4% agreed, 10.8% were 
neutral, 4.3% disagreed while 0.7% strongly disagreed. Cumulatively, 84.2% agreed while 




Figure 25: Respondents’ Views on Reduction in ADR Cases Revealing an Effective Monitoring Practice 
The above responses given by most of the staff shows that when there is an effective 
monitoring practice, there would be a consequent reduction in ADR cases. This implies an 
inverse relationship between an effective ADR monitoring practice and reduction in ADR 
cases.  
4.7 Research Hypotheses 
4.7.1 Hypothesis One: 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the 
Estimate 
1 .299a .089 .083 1.34698 
a. Predictors: (Constant), ADR monitoring 
 



















vi Table 4.3.3: Coefficients 
The first research hypothesis of this study states that NAFDAC ADR monitoring would have no 
impact on the safety of public health.  In Table 4.3 above, we see the Model Summary shows 
the Adjusted R square to be 0.83. This implies that 83% of the variance of public health safety 
can be explained by NAFDAC’s ADR monitoring. Also, Table 4.3.2, the ANOVA gives a 
presentation of the study’s model to be significant. This is because the p-value which is 0.000 
is lesser than the significance level of 0.05. The model significance can be given as, F (1, 137) 
= 13.462, p = 0.000. 
Moreover, as regards Table 4.3.3 which gives a presentation of the regression coefficient of 
ADR monitoring to be 3.669, also showed that ADR monitoring to be with a p-value of 0.000. 
Given the fact that the independent variable is with a p-value of 0.000 which is lesser than 
the significance level of 0.05, the null hypothesis would be rejected while the alternative 
hypothesis would be accepted. Consequent upon this, it can therefore be concluded that ADR 











Regression 24.425 1 24.425 13.462 .000b 
Residual 248.568 137 1.814   
Total 272.993 138    
a. Dependent Variable: Public Health Safety 








B Std. Error Beta 
1 
(Constant) 1.646 .388  4.243 .000 
ADR 
monitoring 
.068 .018 .299 3.669 .000 
a. Dependent Variable: Public Health Safety 
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Sig. (2-tailed)  .001 
N 139 139 





Sig. (2-tailed) .001  
N 139 139 
**. Correlation is significant at the 0.01 level (2-tailed). 
vii Table 4.4: Correlation 
This research hypothesis states that no relationship exists between ADR monitoring and 
reduction in ADR cases. To test this hypothesis, Karl Pearson’s correlation (r) within the 
significance level of 0.05 was used. In Table 4.4, it is seen that a weak positive relationship 
exists between the two variables at 0.274. Moreover, in ascertaining the acceptance or 
rejection of this hypothesis, Table 4.4 shows the p-value to 0.001 which is lesser than the 
significance level of 0.05. As a result of this, the null hypothesis is rejected while the 
alternative hypothesis is accepted. This therefore means that a relationship exists between 
ADR monitoring and reduction in ADR cases.  
4.8 Conclusion 
The analysis and findings of this study have revealed that most NAFDAC staff understand the 
concept of ADR monitoring. This has provided the study with a solid foundation for answering 
its research questions because responses given by the study’s participants can be trusted due 
to their understanding of the study’s main subject matter – ADR monitoring. Forty (40) 
questionnaire items were analysed in accordance with their categorisation on the electronic 
questionnaire. In this chapter, it was identified whether NAFDAC has the capability to 
effectively monitor and address reported ADR cases. Also, the factors that inhibit NAFDAC 
from effectively carrying out the function of ADR monitoring was highlighted and finally 
possible solutions that could aid NAFDAC in fulfilling this obligation was also shown.  
Furthermore, it was discovered that monitoring of ADRs would impact positively on the safety 
of public health and that a positive relationship exists between ADR monitoring and reduction 
in ADR cases. These findings reveal the significant role ADR monitoring plays in safeguarding 
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the public health of the people of a nation. In the health sector of every nation, it is advisable 
for ADR monitoring to be taken seriously due to the significant role it plays in protecting the 
strength of a nation – her people.   
In the subsequent chapter, more conclusions in direct relationship to the research questions 
stated in chapter one shall be provided by the researcher. This chapter will characterise 
comparison between this study’s findings and previous scholarly works and shall recommend 




CHAPTER 5: CONCLUSIONS 
 
5.1 Answering the Three Main Research Questions: 
Question 1: Does NAFDAC have the capability to monitor and address the reported ADR cases? 
Consequent upon the responses given by the study’s participants who are well aware of the 
practice of ADR monitoring, it can be deduced that NAFDAC indeed has the capability to 
monitor and address reported ADR cases. Staff are well aware of the significance of ADR 
monitoring, they are well provided with the required equipment for ADR monitoring, a 
reliable database for the storage of ADR reports is available, the agency also has a good 
network of partners that aids in the collection, review and reports of ADR, a good 
communication network exists between staff and other relevant stakeholders and the staff 
are knowledgeable enough to know what to do when an ADR related drug is discovered or 
reported. These existing features reveal that the Agency has the capability to monitor and 
address every reported ADR case.  
However, despite NAFDAC having this capability to monitor and address every reported ADR 
case, the level of ADR monitoring in the country is still low. This could be as result of some 
challenges that impede the effectiveness of the Agency in the monitoring of ADRs in the 
nation. In the next section, some factors that hinder the Agency’s effective performance in 
the issue of ADR monitoring shall be stated.  
Question 2: What are the factors that hinder NAFDAC from effectively monitoring ADR in 
Nigeria? 
As shown by the survey conducted, staff revealed some major factors that negatively affect 
the agency from effectively monitoring ADRs in the nation. Some of the factors identified by 
staff are similar to those affecting the effective monitoring of ADRs in other African nations. 
These factors include; poor and inconsistent training of staff on recent developments on ADR 
monitoring, neglecting use of latest technological solutions in the monitoring of ADR, poor 
administration of the agency, corruption and conflict of interest, insufficient qualified 
manpower to carry out the activities of ADR monitoring, reluctance of most healthcare 
professionals to report ADR issues due to the fear of litigation or legal matters, and finally 
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consumers of drugs who experience adverse drug reactions do not report their experiences 
to appropriate authorities.  
Despite the capability of NAFDAC to monitor and address ADR cases, these factors are what 
contribute to the inability of the agency to effectively carry out ADR monitoring in the nation. 
For NAFDAC to increase the level of ADR monitoring in the nation, it is expedient that these 
challenges be addressed so as to improve safety of public health. As proven by the study’s 
hypotheses where it was seen that ADR monitoring has a statistically significant impact on 
the safety of public health and that a positive relationship exists between ADR monitoring 
and reduction in ADR cases, the role ADR monitoring plays in the medical sphere of any nation 
cannot be overemphasised.  
Question 3: What are some possible solutions that will help boost ADR monitoring by NAFDAC? 
Having identified the issues that hinder NAFDAC from effectively monitoring ADRs in the 
nation, this section reveals some suggestions that will help boost the monitoring of ADRs by 
NAFDAC. As shown by the quantitative analysis, staff are lacking constant training and hence 
are not up to date with the latest developments in the monitoring practice of ADRs. Due to 
this, it is pertinent for agency to conduct constant trainings that are in tandem with global 
best practices in order to be effective in the monitoring of ADRs. Also, staff should be provided 
with necessary laboratory equipment for further scientific examination of drugs. Although 
this is not a challenge being faced in the agency currently as revealed by the survey, but it is 
expedient for the agency to maintain provision of needed equipment for scientific 
examination of drugs.  
Consequent upon the difficulty being experienced by staff in gaining access to the agency’s 
database, the study recommends that easy access to ADR data stored on the agency’s 
database be granted to staff so as to hasten the process of addressing reported ADR issues. 
There should not be unnecessary protocol for staff to be granted access as that would 
definitely slow down the monitoring process of reported ADR-related issues.  
Moreover, due to the rapid advancement in technology, NAFDAC should be flexible enough 
to adopt recent or latest technological solutions in the monitoring practice of ADRs. This 
would also aid in improving the monitoring process by making it easier and faster to address 
ADR issues. Finally, as revealed by the survey, it is shown that the reluctance of medical 
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practitioners due to fear of litigation and people (patients) who experience adverse drug 
reactions after the use of certain drugs affect negatively the effectiveness of ADR monitoring 
by the agency. Due to these issues, there should be a well-designed program that will educate 
medical practitioners and consumers on the need to report ADR issues so that appropriate 
actions can be taken by NAFDAC for the purpose of reducing the level of ADR-related cases in 
the nation.  
5.2 Comparing and Contrasting Results from Primary and Secondary Research 
Results from the primary research showed that NAFDAC has what it takes to effectively 
monitor and address reported ADR issues but still have been struggling to meet up to 
expectations in this regard. Due to the low level of ADR monitoring in the nation as revealed 
by Opadeyi, Fourrier-Reglat and Isah (2018) who stated that the Nigerian medical system is 
characterised by low level of ADR monitoring, the study sought to reveal the challenges being 
faced by NAFDAC in the implementation of ADR monitoring and to proffer solutions for the 
improvement of the practice for both the safety and good health of the general public in 
Nigeria.  
As revealed by the study’s findings, certain factors hinder NAFDAC from its effective 
monitoring of ADRs in the nation. One of which is corruption and conflict of interest. This was 
also identified by Akunyili (2010) in the literature as one of the major reasons for the poor 
regulation of drugs in the country. According to her many fake drugs have been allowed into 
the market due to the selfish interest of the agency’s officials. The study’s reconfirmation of 
corruption and conflict of interest being a factor affecting effective drug monitoring means 
that adequate attention should be paid to address this issue in order to see an improved ADR 
monitoring system in the nation.  
Another challenge identified by the primary research which NAFDAC faces is insufficient 
qualified manpower to carry out monitoring activities. Insufficiency in the number of qualified 
personnel to advance monitoring activities in the nation is one challenge also identified by 
Olowofela, Fourrier-Reglat and Isah (2016). People (human resources) have been known to 
be the backbone of every organisation. The limitation of every organisation is indirectly the 
limitation of its workforce. For an organisation to move forward, competent hands have to 
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be involved in the activities of the organisation. Consequent upon this understanding, 
NAFDAC has to pay attention to the quality of people it absorbs into its workforce. 
Furthermore, Nwokike (2008) stated that the level of ADR monitoring is contingent upon the 
level of ADR reporting. Primary research conducted showed that the refusal or reluctance of 
medical practitioners and consumers of drugs is one of the challenges that affects the 
effective monitoring of ADRs by the regulatory agency. 
5.3 Concluding Thoughts 
5.3.1 Contributions and Limitations of the Research 
Having generated a sample size of one hundred and fifty-two (152) with a response rate of 
91% (i.e. gaining 139 responses) despite the short duration for the completion of the study, 
data was analysed with the aid of the Statistical Package for Social Sciences (SPSS) of which 
was presented in frequencies and percentages using tables, pie charts and bar charts for 
better explanation and understanding. While there are very little or no research papers on 
ADR monitoring with reference to Nigeria, this study investigated into the reason why the 
level of ADR monitoring in the country is low by revealing that it is not because NAFDAC does 
not have the capability to monitor and address reported ADR cases but that there are some 
challenges which hinder the agency from effectively carrying out its duty in the area of ADR 
monitoring. Responses through the use of electronic survey questionnaires were received 
from staff of NAFDAC operational office in the commercial capital of the nation, Lagos state.  
The major limitation of this study is the dearth in research papers concerning this subject of 
ADR monitoring with respect to Nigeria. This in a way affected the study as there was little or 
no foundation for the study to be built on in the body of knowledge. Moreover, the short time 
frame for the completion of this study is another factor as adequate attention was not paid 
to the study in a bid to meet up with slated deadline for submission.   
Another limitation is that the study focused on a particular branch of NAFDAC, that is, Lagos 
Operational Office, to make conclusions on the capability of the agency and the issues 
affecting the effective monitoring of ADRs in the entire nation by the agency. Using a 
particular branch out of 36 branches is not sufficient enough to conclude on the agency’s 
capability and the issues affecting its effective operations. This calls for further research to be 
carried out to include more branches under investigation. 
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While the study contributed its own quota to the body of knowledge, other areas responsible 
for the low level of ADR monitoring in the nation are yet to be explored. This calls for further 
research to be conducted in order to identify other reasons why the level of ADR monitoring 
is low in the country.  
Finally, in carrying out this study, only the quantitative approach was adopted. This means 
that the study failed to answer more on why ADR monitoring is low in Nigeria. Due to this, 
further study should be carried out with the use of a mixed-method approach in order to 
suffice for the weaknesses in this research.  
5.3.2 Recommendations for Practice 
As revealed by the research findings, one of the challenges affecting NAFDAC’s effective 
monitoring of ADR is the inconsistent training of staff on latest developments in ADR 
monitoring. Not keeping staff abreast with recent developments in the monitoring of ADRs is 
a significant factor that hinders the effective practice of ADR monitoring by the regulatory 
agency. As a result, regular trainings where staff’s knowledge are updated with current trends 
with respect to ADR monitoring should be conducted. 
Furthermore, staff should be granted easy access to the agency’s database in order to hasten 
the process of addressing reported ADR cases. The difficulty experienced by staff in order to 
gain access to the database is one of the major factors that slows down or hinders the 
effective monitoring process of the agency. This issue has to be addressed if the agency is to 
experience an improved performance in the monitoring of ADRs in the nation.  
To further ameliorate the level of impact of NAFDAC on the issue of ADR monitoring, NAFDAC 
should adopt the use of latest technological solutions in the monitoring practice of ADRs. 
Technology is known to make work easier and faster and adopting technological inventions 
or innovations in ADR issues would contribute greatly to the effective monitoring of ADR cases 
by the regulatory agency, NAFDAC in the nation.  
It is without doubt that ADR monitoring stems from the reporting of ADRs. One of the factors 
limiting NAFDAC’s ineffective monitoring of ADR is the reluctance of medical practitioners and 
consumers to report ADR cases. And the when ADR cases are not reported, the practice of 
monitoring cannot be carried out. This is another major factor that deters the agency from 
effectively performing its duties. Consequent upon this, NAFDAC should implement a well-
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designed program for the education of medical practitioners and consumers on the 
importance of ADR reporting. This would enhance NAFDAC’s effectiveness in the monitoring 
process and consequently reduce ADR issues in the nation.   
5.3.3 Recommendations for Future Research 
With respect to ADR monitoring in Nigeria, further research should be conducted to explore 
other reasons why the level of ADR monitoring is low. Due to the dearth in research papers 
on ADR monitoring, it is recommended that further research be carried out in this area so as 
to improve the level of knowledge in this area.  
Moreover, further research should be expanded to include more branches of the regulatory 
agency, NAFDAC. There are branches of NAFDAC in each of the 36 states in Nigeria and it is 
recommended that more than one branch be used as study areas to gain a wider and more 
reliable conclusion on the agency’s capability to monitor and address reported ADR cases and 
to identify other factors that hinder the agency from effectively carrying out the monitoring 
practice of ADRs in the nation.  
Also, this study made use of only the quantitative approach. This means that this study carries 
within it the weakness or cons of quantitative approach. As a result, it is recommended for 
further studies to be carried out with the use of mixed-method approach. A mixed-method 
approach is the combination of both quantitative and qualitative approaches in the study of 
a given phenomenon. The use of this method will aid both approaches to complement their 
strengths and weaknesses thereby giving the research a more credible outcome. These 
recommendations would give a more reliable and deeper understanding on the issue of ADR 
monitoring in Nigeria.  
5.4 Final Conclusions 
In concluding this study on whether NAFDAC has the capability to monitor and address 
reported ADR cases in Nigeria and subsequent to the review of relevant literature on the 
topic, the researcher found this study to be very insightful as it helps in filling existing lacunas 
in the literature concerning ADR monitoring in Nigeria. As earlier mentioned, there is so much 
dearth in the literature on ADR monitoring in Nigeria of which this study addressed.  
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As seen in the literature review, the level of ADR monitoring in Nigeria is lower when 
compared to its African counterpart, Kenya. This is because the Pharmacy and Poison Board, 
the agency responsible for drug regulation in Kenya adopted the use of latest technological 
innovations in their reporting system. The digitised reporting system being used by Kenya 
greatly contributed to the effective monitoring system it currently has. The researcher 
concludes that of a truth the Nigerian regulatory agency, NAFDAC has the capability to 
effectively monitor and address ADR issues but that attention should be given to the use of 
technological solutions in the carrying out of ADR monitoring practices as seen in Kenya. This 
would in turn increase the agency’s effectiveness in the monitoring of ADRs in the nation. 
Moreover, the staff revealed some other factors that hinder the effective monitoring of ADRs 
by NAFDAC. These factors include; poor and inconsistent training of staff, poor administration 
of the agency, corruption and conflict of interest, lack of qualified manpower, reluctance of 
most healthcare professionals to report ADR issues, and consumers who refuse to report ADR 
experiences after consumption of a drug.  
Most of the staff opted for the organising of constant trainings that are in line with global best 
practices so as to have a competent workforce that can effectively carry out ADR monitoring 
in the nation. This shows the willingness of staff to improve themselves in order for the agency 
to be effective in its duties. The researcher also points out that while NAFDAC has the 
capability to monitor and address reported ADR cases, they have not utilised that capability 
in ensuring ADR monitoring is effectively done. This might be due to factors such as poor 
administration, corruption and conflict of interest, etc as aforementioned.  
Due to the foregoing, it is expedient for the administrative arm of NAFDAC to take cognisance 
of all the factors stated in this study that hinder the agency from effectively monitoring ADRs 
in the nation and address them. Only when this is done would the impact of the agency be 
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